

CITATION REPORT

List of articles citing

Clinical Classification of Cases of Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome, and Erythema Multi

DOI: 10.1001/archderm.1993.01680220104023
Archives of Dermatology, 1993, 129, 92.

Source: <https://exaly.com/paper-pdf/24402231/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
936	Toxic epidermal necrolysis in a patient suffering from acquired immune deficiency syndrome. 1994 , 22, 365		3
935	Syndrome de Lyell. 1994 , 34, 399-402		
934	Stevens-Johnson syndrome after terbinafine therapy. 1994 , 30, 509		35
933	Cutaneous drug reactions. 1994 , 6, 83-122		9
932	An autopsy case of malignant lymphoma with Lyell's syndrome. 1995 , 22, 594-9		7
931	Toxic epidermal necrolysis associated with Mycoplasma pneumoniae infection. 1995 , 14, 558-9		62
930	Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2-antagonists. 1995 , 4, 207-212		1
929	Epidemiology of Adverse Cutaneous Reactions to Drugs. 1995 , 13, 681-688		10
928	An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. 1995 , 48, 1099-108		55
927	Drug-induced severe skin reactions. Incidence, management and prevention. 1995 , 13, 56-68		69
926	Le syndrome de choc toxique staphylococcique (Toxic Shock Syndrome) au cours de l'infection par le VIH: un diagnostic ^ ne pas m^connaître (^ propos de 4 cas). 1995 , 25, 904-913		
925	Epidemiology of drug-induced severe skin reactions. 1996 , 15, 236-43		46
924	Advances in toxic epidermal necrolysis. 1996 , 15, 258-66		44
923	Dermatologic problems encountered in the emergency department. 1996 , 14, 588-601		2
922	Photo-induced toxic epidermal necrolysis caused by clobazam. 1996 , 135, 999-1002		47
921	Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. 1996 , 135, 6-11		24
920	Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. 1996 , 135, 864-6		17

919	Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. 1996 , 134, 710-4	202
918	Phenytoin-induced toxic epidermal necrolysis: a case report. 1996 , 21, 116-120	7
917	Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. 1997 , 24, 726-9	129
916	Phenolphthalein-induced toxic epidermal necrolysis. 1997 , 31, 1157-9	5
915	Toxic epidermal necrolysis after treatment with lamotrigine (Lamictal). 1997 , 6, 63-5	44
914	Les réactions cutanées sévères induites par les médicaments. 1997 , 37, 651-659	
913	Acrosyringeal concentration of necrotic keratinocytes in erythema multiforme: a clue to drug etiology. Clinicopathologic review of 29 cases. 1997 , 24, 235-40	25
912	Toxic epidermal necrolysis. 1998 , 351, 1417-20	113
911	Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. 1998 , 352, 1586-9	345
910	The histopathology of drug rashes. 1998 , 5, 138-149	3
909	Stevens-Johnson syndrome caused by a health drink (Eberu) containing ophiopogonis tuber. 1998 , 25, 662-5	22
908	Toxic epidermal necrolysis. 1998 , 9, 35-37	5
907	Erythema multiforme secondary to amoxicillin/clavulanic acid exposure. 1999 , 33, 109-10	2
906	Nevirapine-induced overlap stevens-johnson syndrome/toxic epidermal necrolysis. 1999 , 140, 980-2	19
905	Allergic emergencies encountered by the dermatologist. Severe cutaneous adverse drug reactions. 1999 , 17, 497-511	4
904	Anticonvulsant-Induced Cutaneous Reactions. 1999 , 12, 215-236	12
903	Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. 1999 , 353, 2190-4	285
902	Treatment of severe drug eruptions. 1999 , 26, 718-22	61

901	Management of drug-induced toxic epidermal necrolysis. 2000 , 4, 96-102	9
900	Management of toxic epidermal necrolysis. 2000 , 61, 778-81	14
899	Taking aim at erythema multiforme. How to spot target lesions and less typical presentations. 2000 , 107, 87-90	3
898	A case of toxic epidermal necrolysis-type drug eruption induced by oral lysozyme chloride. 2000 , 27, 401-4	5
897	Immunoregulatory effector cells in drug-induced toxic epidermal necrolysis. 2000 , 22, 413-7	68
896	SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. 2000 , 115, 149-53	634
895	Nitric oxide synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. 2000 , 114, 196-9	49
894	Toxic epidermal necrolysis associated with acetaminophen ingestion. 2000 , 34, 32-4	43
893	Parvovirus infection of keratinocytes as a cause of canine erythema multiforme. 2000 , 37, 647-9	29
892	Prospects for control of herpes simplex virus disease through immunization. 2000 , 30, 549-66	163
891	Drug eruptions. 2000 , 12, 58-62	2
890	Idiosyncratic drug reactions: the reactive metabolite syndromes. 2000 , 356, 1587-91	271
889	Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 2000 , 1, 349-60	114
888	Toxic epidermal necrolysis. 2000 , 18, 485-95, ix	40
887	New advances in severe adverse drug reactions. 2001 , 19, 697-709, ix	21
886	Quand la peau suscite l'ârgence. 2001 , 41, 331-335	
885	Sândrome de Stevens-Johnson/necrôsis epidêmica tãica. 2001 , 16, 444-457	7
884	Severe Cutaneous Adverse Reactions to Medications. 2001 , 4, 171-185	1

883	Drug eruptions in children. 2001 , 31, 207-234	33
882	Toxic epidermal necrolysis induced by nevirapine therapy: description of two cases and review of the literature. 2001 , 43, 246-9	19
881	Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. 2001 , 51, 174-6	6
880	Trimethoprim/sulfamethoxazole-induced toxic epidermal necrolysis. 2001 , 35, 694-7	15
879	Interventions for toxic epidermal necrolysis. 2002 , CD001435	14
878	Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years' experience. 2002 , 25, 965-72	145
877	Drug eruptions in children. 2002 , 14, 153-182	2
876	Increased interleukin 10, tumor necrosis factor alpha, and interleukin 6 levels in blister fluid of toxic epidermal necrolysis. 2002 , 47, 58-62	67
875	Drug eruptions and other adverse drug effects in aged skin. 2002 , 18, 21-42	25
874	Alteraci3n pulmonar y renal en s3ndrome de Stevens-Johnson de evoluci3n fatal. Estudio anatomopatol3gico. 2002 , 57, 71-73	2
873	Toxic epidermal necrolysis in a pregnant, HIV-infected woman. 2002 , 41, 600-1	11
872	Tolerability and pharmacokinetics of oral loading with lamotrigine in epilepsy monitoring units. 2003 , 44, 536-9	13
871	Oral manifestations of erythema multiforme. 2003 , 21, 195-205	126
870	Dos casos de necrosis epid3rmica t3xica localizada asociada a radioterapia. 2003 , 94, 475-478	3
869	Photo-induced Stevens-Johnson syndrome due to sulfasalazine therapy. 2003 , 37, 1241-3	12
868	Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. 2003 , 162, 1515-20	450
867	Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions : implications for management. 2003 , 4, 407-28	52
866	Differential diagnosis of severe cutaneous drug eruptions. 2003 , 4, 561-72	123

865	Stevens-Johnson syndrome associated with Malarone antimalarial prophylaxis. 2003 , 37, e5-7	19
864	Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases. <i>Archives of Dermatology</i> , 2003 , 139, 26-32	504
863	Possible cefotaxime-induced Stevens-Johnson syndrome. 2003 , 37, 812-4	10
862	Treatment of Toxic Epidermal Necrolysis With Moisture-Retentive Ointment. 2003 , 29, 185-188	11
861	Outbreak of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. 2003 , 93, 489-92	34
860	Spectrum of anticonvulsant hypersensitivity syndrome: controversy of treatment. 2004 , 19, 619-23	5
859	Complications of therapy in cancer patients: Case 3. Toxic epidermal necrolysis induced by oral phenobarbital and whole-brain radiotherapy in a breast cancer patient. 2004 , 22, 4649-51	10
858	Possible involvement of gelatinase A (MMP2) and gelatinase B (MMP9) in toxic epidermal necrolysis or Stevens-Johnson syndrome. 2004 , 296, 220-5	18
857	Human herpesvirus infection in drug-induced hypersensitivity syndrome, toxic epidermal necrolysis and Stevens-Johnson syndrome. 2004 , 53, 23-29	6
856	Assessment and management of cutaneous reactions with amifostine administration: findings of the ethylol (amifostine) cutaneous treatment advisory panel (ECTAP). 2004 , 60, 302-9	25
855	Toxicodermias immunoalérgicas en pacientes inmunocompetentes. 2004 , 38, 1-8	
854	Stevens-Johnson syndrome after immunization with smallpox, anthrax, and tetanus vaccines. 2004 , 79, 1193-6	8
853	Toxidermies immunoallergiques chez lâimmunocomptent. 2004 , 1, 75-86	0
852	Esophageal stricture as a late sequel of Stevens-Johnson syndrome in adults: incidental detection because of foreign body impaction. 2004 , 59, 437-40	10
851	Stevens-Johnson Syndrome After Immunization With Smallpox, Anthrax, and Tetanus Vaccines. 2004 , 79, 1193-1196	18
850	Intravenous immunoglobulin for treatment of toxic epidermal necrolysis. 2005 , 329, 95-8	10
849	Review of common cutaneous adverse drug reactions. 2005 , 47, 27-29	
848	High-dose intravenous immunoglobulins in the treatment of toxic epidermal necrolysis: an Asian series. 2005 , 32, 1-6	40

847	Heterotopic ossification related to toxic epidermal necrolysis in a patient with Behçet's disease. 2005 , 32, 469-73	5
846	High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. 2005 , 19, 846-53	54
845	Lyell syndrome revisited: analysis of 18 cases of severe bullous skin disease in a burns unit. 2005 , 58, 73-80	15
844	Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. 2005 , 58, 504-10	50
843	[Severe cutaneous adverse drug reactions. Clinical features and epidemiology]. 2005 , 56, 24-31	11
842	Analytical quantification of the inflammatory cell infiltrate and CD95R expression during treatment of drug-induced toxic epidermal necrolysis. 2005 , 297, 266-73	18
841	Toxic epidermal necrolysis (TEN) Lyell's syndrome. 2005 , 16, 278-86	19
840	[Persistant mucosal ulcerations: a rare complication of toxic epidermal necrolysis]. 2005 , 132, 682-5	6
839	[Acquired bullous diseases of the oral mucosa]. 2005 , 106, 287-97	1
838	[Stevens-Johnson syndrome and toxic epidermal necrolysis in Lom ^o (Togo). Evolutional and etiological profiles of 40 cases]. 2005 , 132, 531-4	9
837	Mycoplasma pneumoniae-induced Stevens-Johnson syndrome without skin lesions: fact or fiction?. 2005 , 52, 312-5	68
836	Erythema multiforme: a review and contrast from Stevens-Johnson syndrome/toxic epidermal necrolysis. 2005 , 49, 67-76, viii	43
835	Serious drug rashes in children. 2005 , 52, 207-22	
834	Treatment of epidermal necrolysis with high-dose intravenous immunoglobulins (IV Ig): clinical experience to date. 2005 , 65, 2085-90	57
833	Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. 2006 , 7, 359-68	37
832	Toxic epidermal necrolysis in patient with breast cancer receiving letrozole. 2006 , 7, 184-5	4
831	Penicillins. 2006 , 2756-2772	
830	Adverse cutaneous drug eruptions and HIV: a clinician's global perspective. 2006 , 24, 459-72, vi	21

829	36-year-old man with productive cough and diffuse rash. 2006 , 81, 945-8	3
828	[Odinophagia and cutaneous lesions in patient with cerebral metastases]. 2006 , 206, 251-3	
827	Rash and fever. 2006 , 31, 293-7	3
826	Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. 2006 , 6, 543-9	89
825	Toxic epidermal necrolysis and intravenous immunoglobulin: a review. 2006 , 25, 91-3	31
824	[Stevens-Johnson syndrome and toxic epidermal necrolysis]. 2006 , 97, 177-85	19
823	Toxic epidermal necrolysis with combination lamotrigine and valproate in bipolar disorder. 2006 , 30, 147-50	11
822	Human herpesvirus 6 reactivation in trichloroethylene-exposed workers suffering from generalized skin disorders accompanied by hepatic dysfunction. 2006 , 48, 417-23	44
821	Toxidermies immunoallergiques chez l'immunocompétent. 2006 , 1, 1-7	
820	Sultamicillin-induced Stevens-Johnson syndrome. 2006 , 9, 192-193	
819	The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. 2006 , 154, 319-24	37
818	Elevated circulating CD40 ligand in patients with erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. 2006 , 154, 1006-7	16
817	Sera from patients with toxic epidermal necrolysis contain autoantibodies to periplakin. 2006 , 155, 337-43	10
816	Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. 2006 , 155, 722-8	78
815	Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. 2006 , 126, 272-6	146
814	[Treatment of toxic epidermal necrolysis. Experience with 9 patients with consideration of intravenous immunoglobulin]. 2006 , 57, 185-6, 188-90, 192-4	11
813	Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. 2006 , 55, 9-16	155
812	Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. 2006 , 42, 312-20	24

811	Drug Rash with eosinophilia and systemic symptoms versus Stevens-Johnson Syndrome--a case that indicates a stumbling block in the current classification. 2006 , 141, 308-10	19
810	Canadian consensus statement on the use of intravenous immunoglobulin therapy in dermatology. 2006 , 10, 205-21	24
809	Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. 2007 , 20, 557-66	17
808	Emergencies in dermatology: diagnosis, classification and therapy. 2007 , 2, 549-562	4
807	Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. 2007 , 56, 419-25	86
806	Management of scalp toxic epidermal necrolysis and cranial osteomyelitis with serratus anterior myocutaneous pedicle flap: a case report. 2007 , 28, 524-9	5
805	Syndrome de Lyell (nẽcrolyse ẽidermique toxique). 2007 , 2, 1-13	
804	Approach to the acute, generalized, blistering patient. 2007 , 26, 139-46	12
803	New grading system for the evaluation of chronic ocular manifestations in patients with Stevens-Johnson syndrome. 2007 , 114, 1294-302	199
802	Stevens-Johnson syndrome due to concomitant use of lamotrigine and valproic acid. 2007 , 8, 107-11	15
801	[Global management of cutaneous adverse drug reactions]. 2007 , 134, 391-401	8
800	[Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome]. 2007 , 67, 68-73	3
799	Drug-induced skin, nail and hair disorders. 2007 , 30, 1011-30	93
798	Acute Dermatologic Emergencies. 2007 , 97-113	
797	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2007 , 1016-1019	1
796	Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. 2007 , 127, 802-7	52
795	Conjunctival pigmentation in Stevens-Johnson syndrome. 2007 , 39, 152-7	2
794	Stevens-Johnson syndrome in children receiving phenobarbital therapy and cranial radiotherapy. 2007 , 85, 213-5	8

793	Management of dysphagia in toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS). 2007 , 22, 187-92	12
792	Intravenous immunoglobulins for the management of Stevens-Johnson syndrome with minimal skin manifestations. 2007 , 166, 585-8	20
791	Conjunctival pigmentation in Stevens-Johnson syndrome. 2007 , 33, 99-103	0
790	Erythema multiforme and Stevens-Johnson syndrome following radiotherapy. 2007 , 25, 27-30	11
789	Erythema multiforme after radiotherapy with aromatase inhibitor administration in breast-conservation treatment for breast cancer. 2008 , 15, 321-3	7
788	Lack of evidence for erythema multiforme in skin reaction to adalimumab: comment on the article by Beuthien et al. 2008 , 58, 1205-6; author reply 1206	0
787	Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. 2008 , 128, 35-44	625
786	Herpes zoster virus associated 'sparing phenomenon': is it an innate possess of HZV or keratinocyte cytokine(s) mediated or combination?. 2008 , 22, 1373-5	10
785	Energy requirements of pediatric patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2008 , 23, 547-50	34
784	Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. 2008 , 58, 25-32	312
783	Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. 2008 , 58, 33-40	341
782	Toxic epidermal necrolysis with a rare long-term oral complication requiring surgical intervention. 2008 , 105, e29-33	15
781	Eritema polimorfo. 2008 , 42, 1-9	
780	Management of toxic epidermal necrolysis and related syndromes. 2008 , 84, 60-5	26
779	Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. 2008 , 40, 129-38	65
778	Erythème polymorphe. 2008 , 3, 1-9	2
777	Human immunodeficiency virus-infected boy with Stevens-Johnson syndrome caused by nevirapine. 2008 , 27, 1041-2	3
776	Cutaneous drug eruptions by current antiepileptics: case reports and alternative treatment options. 2008 , 31, 93-6	16

775	Toxic epidermal necrolysis induced by sulfonamide eyedrops. 2008 , 27, 1068-9	10
774	Toxic epidermal necrolysis clinical guidelines. 2008 , 29, 706-12	58
773	Erupciones inflamatorias y purpúricas. 2009 , 311-342	
772	Fluconazole induced toxic epidermal necrolysis: a case report. 2009 , 2, 9071	9
771	Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome. 2009 , 182, 8071-9	193
770	Two cases of Stevens-Johnson syndrome following intake of klavox with review of literature. 2009 , 266, 1327-30	6
769	[Stomatitis, cheilitis and conjunctivitis after a common cold]. 2009 , 57, 914-7	2
768	Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: a retrospective comparative study in China. 2009 , 48, 1122-8	63
767	Severe drug-induced skin reactions: clinical pattern, diagnostics and therapy. 2009 , 7, 142-60; quiz 161-2	42
766	The International Society for Bipolar Disorders (ISBD) consensus guidelines for the safety monitoring of bipolar disorder treatments. 2009 , 11, 559-95	125
765	Clinical risk management of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. 2009 , 22, 441-51	34
764	Docetaxel-induced Stevens-Johnson syndrome with regenerating epidermis composed of atypical keratinocytes. 2009 , 23, 1333-5	13
763	Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. 2009 , 116, 685-90	121
762	Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. 2009 , 147, 1004-11, 1011.e1	109
761	Acute management of Stevens-Johnson syndrome and toxic epidermal necrolysis to minimize ocular sequelae. 2009 , 147, 949-51	15
760	Vision-related function after scleral lens fitting in ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. 2009 , 148, 852-9.e2	56
759	[Mycoplasma pneumoniae-induced severe mucositis]. 2009 , 71, 573-4	4
758	Stevens-Johnson Syndrome and toxic epidermal necrolysis overlap due to oral temozolomide and cranial radiotherapy. 2009 , 10, 264-7	21

757 60-Year-Old Man With Rash. **2009**, 84, 838-841

756 An update on Stevens-Johnson syndrome and toxic epidermal necrolysis in children. **2009**, 21, 505-10 54

755 Stevens-Johnson syndrome and toxic epidermal necrolysis: consequence of treatment of an emerging pathogen. **2009**, 25, 519-22 7

754 Toxic epidermal necrolysis in a child after carbamazepine dosage increment. **2009**, 25, 93-5 5

753 Dermatoses vřiculeuses et bulleuses aux urgences. **2010**, 5, 1-12 1

752 High-level human herpesvirus-6 viremia associated with onset of Stevens-Johnson syndrome: report of two cases. **2010**, 31, 365-8 16

751 Toxic epidermal necrolysis in pregnancy: case report and review of the literature. **2010**, 31, 816-21 19

750 Paraneoplastic pemphigus in a burn intensive care unit: case report and review of the literature. **2010**, 31, 826-9 6

749 Successfully changing an ICD-9 diagnosis code: the ABA experience for Stevens-Johnson syndrome and toxic epidermal necrolysis. **2010**, 31, 146-50 3

748 Severe cutaneous adverse reactions: emergency approach to non-burn epidermolytic syndromes. **2010**, 36, 22-32 41

747 Eritema multiforme. **2010**, 17, 436-437

746 HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. **2010**, 51, 2461-5 182

745 Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: frozen-section diagnosis. **2010**, 37, 407-12 23

744 Differences in immunological alterations and underlying viral infections in two well-defined severe drug eruptions. **2010**, 35, 863-8 31

743 Update on the management of antibiotic allergy. **2010**, 2, 77-86 37

742 The lichenoid reaction pattern (ã[interface dermatitisã]) **2010**, 35-70.e41 6

741 A Clinical Study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Efficacy of Treatment in Burn Intensive Care Unit. **2010**, 78, 133 3

740 Systemic inflammatory response syndrome in diseases of the skin. **2010**, 86, 83-8 6

739	Pharmacogenetics of drug hypersensitivity. 2010 , 11, 973-87	90
738	Prediction of severe adverse drug reactions using pharmacogenetic biomarkers. 2010 , 25, 122-33	21
737	Bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: epidemiology, risk factors, and predictive value of skin cultures. 2010 , 89, 28-36	60
736	[Cicatricial conjunctivitis]. 2010 , 33, 577-85	0
735	Clinical, etiologic, and histopathologic features of Stevens-Johnson syndrome during an 8-year period at Mayo Clinic. 2010 , 85, 131-8	96
734	[Clinical assessment of the risk of bacteremia and the value of skin cultures during Stevens-Johnson syndrome and toxic epidermal necrolysis]. 2010 , 137, 651-2	
733	[Oral disease in children]. 2010 , 137, 823-37	2
732	Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. 2010 , 67, 206-13	58
731	CD94/NKG2C is a killer effector molecule in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2010 , 125, 703-10, 710.e1-710.e8	48
730	Association between prostaglandin E receptor 3 polymorphisms and Stevens-Johnson syndrome identified by means of a genome-wide association study. 2010 , 126, 1218-25.e10	53
729	Toxic epidermal necrolysis after sun-exposure probably due to lamotrigine and chlorpromazine. 2010 , 3, 240-2	6
728	Pharmacogenetics of toxic epidermal necrolysis. 2010 , 11, 2153-62	13
727	New insights in toxic epidermal necrolysis (Lyell's syndrome): clinical considerations, pathobiology and targeted treatments revisited. 2010 , 33, 189-212	34
726	Ophthalmic Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis and Relation to SCORTEN. 2010 , 150, 505-510.e1	60
725	The ophthalmologist's role in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis. 2010 , 8, 193-203	21
724	Severe carbamazepine-induced cutaneous reaction in the treatment of post-herpetic neuralgia. Case report. 2010 , 60, 429-37	4
723	Pharmacogenetic considerations in the treatment of psychiatric disorders. 2010 , 11, 423-39	22
722	Early gynaecological assessment following Stevens-Johnson syndrome/toxic epidermal necrolysis. 2010 , 30, 871-2	3

721	A world allergy organization international survey on diagnostic procedures and therapies in drug allergy/hypersensitivity. 2011 , 4, 257-70	35
720	The current understanding of Stevens-Johnson syndrome and toxic epidermal necrolysis. 2011 , 7, 803-13; quiz 814-5	181
719	Drug hypersensitivity: pharmacogenetics and clinical syndromes. 2011 , 127, S60-6	129
718	Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2011 , 78.1-78.8	2
717	Patient experiences of serious adverse drug reactions and their attitudes to medicines: a qualitative study of survivors of Stevens-Johnson syndrome and toxic epidermal necrolysis in the UK. 2011 , 34, 319-28	40
716	[Stevens-Johnson and Lyell syndromes: mucocutaneous and ocular sequels in 43 cases]. 2011 , 138, 88-92	9
715	Seasonal variation of Stevens-Johnson syndrome and toxic epidermal necrolysis associated with trimethoprim-sulfamethoxazole. 2011 , 64, 1193-4	3
714	Drug eruptions in dermatology. 2011 , 6, 273-286	8
713	SEVERE, ACUTE ADVERSE CUTANEOUS DRUG REACTIONS I: STEVENS-JOHNSON SYNDROME AND TOXIC EPIDERMAL NECROLYSIS. 154-161	1
712	Stevens-johnson syndrome induced by vandetanib. 2011 , 23, S343-5	21
711	 Erythema multiforme minor in a dog following inappropriate intranasal Bordetella bronchiseptica vaccination: a case report. 2011 , 56, 568-572	2
710	Management of treatment-related dermatologic adverse effects. 2011 , 115-120	
709	Toxic epidermal necrolysis associated with sorafenib and tosufloxacin in a patient with hepatocellular carcinoma. 2011 , 23, S404-7	8
708	Epidemiology and risk factors for drug allergy. 2011 , 71, 684-700	196
707	Evaluation of serum cytokine levels in toxic epidermal necrolysis and Stevens-Johnson syndrome compared with other delayed-type adverse drug reactions. 2011 , 38, 1076-9	11
706	Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. 2011 , 12, 118	139
705	EMPACT syndrome. 2011 , 30, 328-30	7
704	Statistical analysis of Stevens-Johnson syndrome caused by Mycoplasma pneumonia infection in Japan. 2011 , 60, 525-32	38

703	Adverse events after the use of benznidazole in infants and children with Chagas disease. 2011 , 127, e212-8	111
702	Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. 2011 , 2, 87-94	55
701	Toxic epidermal necrolysis associated with TS-1 in a patient with gastric cancer. 2011 , 41, 666-8	6
700	Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 2011 , 128, 723-8	110
699	Toxic epidermal necrolysis and Stevens-Johnson syndrome: a review. 2011 , 39, 1521-32	135
698	Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. 2011 , 20, 1034-41	397
697	How epidemiology has contributed to a better understanding of skin disease. 2012 , 132, 994-1002	7
696	Allopurinol is the most frequent cause of Stevens-Johnson syndrome and toxic epidermal necrolysis. 2012 , 7, 213-215	2
695	Genome-wide association study of serious blistering skin rash caused by drugs. 2012 , 12, 96-104	28
694	Drug-induced hypersensitivity syndrome: recent advances in drug allergy. 2012 , 7, 539-547	6
693	Toxic epidermal necrolysis: performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China. 2012 , 33, e295-308	47
692	The last word on the so-called 'Rowell's syndrome'?. 2012 , 21, 577-85	33
691	A recent update of pharmacogenomics in drug-induced severe skin reactions. 2012 , 27, 132-41	28
690	Toxic epidermal necrolysis and Stevens-Johnson syndrome in South Africa: a 3-year prospective study. 2012 , 105, 839-46	27
689	Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. 2012 , 31, 1394-402	62
688	The role of prior corticosteroid use on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control analysis of patients selected from the multinational EuroSCAR and RegiSCAR studies. 2012 , 167, 555-62	55
687	Internet accounts of serious adverse drug reactions: a study of experiences of Stevens-Johnson syndrome and toxic epidermal necrolysis. 2012 , 35, 1159-70	33
686	[Dermatological conditions requiring intensive care]. 2012 , 63, 727-36; quiz 737-8	1

685	Incidence of toxic epidermal necrolysis and Stevens-Johnson Syndrome in an HIV cohort: an observational, retrospective case series study. 2012 , 13, 49-54	73
684	Skin and Bone Disorders. 2012 , 319-349	1
683	Safety and tolerability of antiepileptic drug treatment in children with epilepsy. 2012 , 35, 519-33	34
682	Pharmacogenetics of Adverse Drug Reactions. 2012 , 295-321	1
681	Toxic epidermal necrolysis in a 15-month-old girl successfully treated with amniotic membrane transplantation. 2012 , 16, 478-80	8
680	Skin signs of severe systemic medication reactions. 2012 , 42, 193-7	
679	Syndrom de Stevens-Johnson. 2012 , 19, 622-623	
678	Acute compartment syndrome of the forearm as a rare complication of toxic epidermal necrolysis: a case report. 2012 , 6, 84	1
677	Pharmacogenetics in psychiatry. 53-68	2
676	Causes and treatment outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in 82 adult patients. 2012 , 27, 203-10	38
675	Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications. 2012 , 21, 289-96	24
674	Drug-induced Stevens-Johnson syndrome: case series from tertiary care centre in Gujarat. 2012 , 21, 384-95	7
673	Validation of a claims-based diagnostic code for Stevens-Johnson syndrome in a commercially insured population. 2012 , 21, 760-764	7
672	Lenalidomide cutaneous adverse event: a case of Stevens-Johnson syndrome (SJS) in a primary plasma cell leukaemia patient treated with lenalidomide and dexamethasone. 2012 , 20, 1585-7	3
671	Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature. 2012 , 166, 575-600	48
670	A comprehensive 4-year survey of adverse drug reactions using a network-based hospital system. 2012 , 37, 647-51	15
669	Mycoplasma pneumoniae and mucositis--part of the Stevens-Johnson syndrome spectrum. 2012 , 10, 740-6	32
668	Distinguishing between erythema multiforme major and Stevens-Johnson syndrome/toxic epidermal necrolysis immunopathologically. 2012 , 39, 781-6	16

667	Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong. 2012 , 167, 44-9	64
666	Clinical features, diagnosis, and treatment of erythema multiforme: a review for the practicing dermatologist. 2012 , 51, 889-902	160
665	Stevens-Johnson syndrome and toxic epidermal necrolysis overlap in a patient receiving cetuximab and radiotherapy for head and neck cancer. 2012 , 51, 864-7	16
664	Umbilical cord mesenchymal stem cell transplantation in drug-induced Stevens-Johnson syndrome. 2013 , 27, 659-61	12
663	Atteintes bronchopulmonaires au cours des toxidermies graves. 2013 , 22, 73-79	1
662	Toxic epidermal necrolysis: Part I. Introduction, history, classification, clinical features, systemic manifestations, etiology, and immunopathogenesis. 2013 , 69, 173.e1-13; quiz 185-6	185
661	Genetic association of IFN- γ -874T/A polymorphism in Mexican patients with drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 2013 , 305, 353-7	1
660	Stevens-Johnson syndrome complicating adalimumab therapy in rheumatoid arthritis disease. 2013 , 33, 1351-3	13
659	Eritema multiforme fotodistribuido. 2013 , 104, 645-653	8
658	[Epidemiological, aetiological and progression profiles of Stevens-Johnson syndrome and toxic epidermal necrolysis in Conakry (Guinea)]. 2013 , 140, 544-6	0
657	A case of toxic epidermal necrolysis-like skin lesions with systemic lupus erythematosus and review of the literature. 2013 , 22, 839-46	25
656	Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. 2013 , 69, 407-15	46
655	Erythema multiforme major following treatment with infliximab. 2013 , 115, e36-40	18
654	Epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis): Historical considerations. 2013 , 31, 169-174	6
653	Immunoglobulin injection for the treatment of multiple oral ulcers in Stevens-Johnson syndrome. 2013 , 14, 355-8	3
652	Bronchiolitis obliterans associated with Stevens-Johnson Syndrome: histopathological bronchial reconstruction of the whole lung and immunohistochemical study. 2013 , 8, 134	16
651	The role of intravenous immunoglobulin in toxic epidermal necrolysis: a retrospective analysis of 64 patients managed in a specialized centre. 2013 , 169, 1304-9	76
650	Prognostic value of histologic features of toxic epidermal necrolysis. 2013 , 68, e29-35	25

649	Photodistributed erythema multiforme. 2013 , 104, 645-53	3
648	A dire reaction: rash after amiodarone administration. 2013 , 126, 301-3	4
647	Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa: a multicentric study in four countries. 2013 , 52, 575-9	28
646	A review of causes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 2013 , 98, 998-1003	80
645	Question 2: Would systemic steroids be useful in the management of Stevens-Johnson syndrome?. 2013 , 98, 828-30	9
644	In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test. 2013 , 43, 1027-37	92
643	Stevens-Johnson syndrome/toxic epidermal necrolysis mouse model generated by using PBMCs and the skin of patients. 2013 , 131, 434-41.e1-9	20
642	Methylprednisolone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis: clinical evaluation and analysis of biomarkers. 2013 , 69, 496-8	38
641	Clinical Stevens-Johnson syndrome and rufinamide: a clinical case. 2013 , 41, 68-9	8
640	Urticaria multiforme in an 18-year-old girl. 2013 , 1, 520-1	4
639	Acute blistering diseases on the burn ward: Beyond Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2013 , 39, 1290-6	3
638	SCORTEN and impaired renal function related to mortality of toxic epidermal necrolysis syndrome patients in the Asian population. 2013 , 27, 628-33	18
637	Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2013 , 168, 726-32	67
636	Pharmacogenomics of severe cutaneous adverse reactions and drug-induced liver injury. 2013 , 58, 317-26	58
635	Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2013 , 231-241	1
634	The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. 2013 , 4, 246-53	21
633	Clinical features and prognostic factors in severe cutaneous drug reactions. 2013 , 162, 346-54	34
632	French referral center management of Stevens-Johnson syndrome/toxic epidermal necrolysis. 2013 , 31, 191-195	13

631	In vitro diagnostic assays are effective during the acute phase of delayed-type drug hypersensitivity reactions. 2013 , 168, 539-49	50
630	Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. 2013 , 169, 1071-80	439
629	Lack of a specific humoral autoreactivity in sera from patients with early erythema exsudativum multiforme majus. 2013 , 133, 2799-2802	3
628	A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. 2013 , 13, 60-9	130
627	Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2013 , 133, 1197-204	231
626	Management of Hyperuricemia and Gout. 2013 , 291-385	
625	A case of microstomia subsequent to toxic epidermal necrolysis surgically treated by simple technique. 2013 , 1, e21	2
624	Stevens-Johnson syndrome and HIV in children in Swaziland. 2013 , 32, 1354-8	8
623	Serum antibody response to group II chaperonin from <i>Methanobrevibacter oralis</i> and human chaperonin CCT. 2013 , 68, 12-9	13
622	Iron complex, dabigatran and toxic epidermal necrolysis syndrome: a case-report. 2013 , 38, 177-8	7
621	Pediatric toxic epidermal necrolysis: an institutional review of patients admitted to an intensive care unit. 2013 , 34, e351-8	13
620	Types of Dermatologic Reactions. 2013 , 33-46	
619	Toxic epidermal necrolysis induced by lansoprazole. 2013 , 88, 117-20	8
618	A 13-year-old boy with pharyngitis, oral ulcers, and dehydration. <i>Mycoplasma pneumoniae</i> -associated mucositis. 2013 , 42, 148-50	7
617	Stevens-Johnson syndrome / toxic epidermal necrolysis: an Asia-Pacific perspective. 2013 , 3, 215-23	32
616	Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome. 2013 , 27, 331-40	32
615	<i>Mycoplasma pneumoniae</i> --associated mucocutaneous disease in children: dilemmas in classification. 2014 , 31, 670-5	11
614	The dynamics of herpesvirus reactivations during and after severe drug eruptions: their relation to the clinical phenotype and therapeutic outcome. 2014 , 69, 798-805	68

613	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2014 , 578-585	1
612	Life-threatening dermatologic adverse events in oncology. 2014 , 25, 225-34	45
611	Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis syndrome in patients undergoing radiation therapy: a literature review. 2014 , 37, 506-13	22
610	Acute respiratory failure in patients with toxic epidermal necrolysis: clinical features and factors associated with mechanical ventilation. 2014 , 42, 118-28	49
609	Dermatological Adverse Drug Reactions. 2014 , 503-512	1
608	A successful pregnancy outcome after Stevens-Johnson Syndrome. 2014 , 34, 445-6	6
607	Generalized bullous fixed drug eruption is distinct from Stevens-Johnson syndrome/toxic epidermal necrolysis by immunohistopathological features. 2014 , 70, 539-48	62
606	[Stevens-Johnson syndrome and Hodgkin's disease: A fortuitous association or paraneoplastic syndrome?]. 2014 , 141, 134-40	2
605	Antiepileptic drugs toxicity: A case of toxic epidermal necrolysis in patient with phenytoin prophylaxis post-cranial radiation for brain metastases. 2014 , 22, 381-4	4
604	HIV infection predisposes skin to toxic epidermal necrolysis via depletion of skin-directed CD4+ T cells. 2014 , 70, 1096-102	26
603	Severe cutaneous adverse reactions related to systemic antibiotics. 2014 , 58, 1377-85	73
602	[Formula: see text]evidence of neuropsychological dysfunction in Stevens-Johnson Syndrome and toxic epidermal necrolysis: case report. 2014 , 28, 841-50	1
601	Clinical application of pharmacogenomics: the example of HLA-based drug-induced toxicity. 2014 , 17, 248-55	11
600	Erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparative review. 2014 , 25, 406-e64	36
599	HLA-A*31:01 and different types of carbamazepine-induced severe cutaneous adverse reactions: an international study and meta-analysis. 2014 , 14, 281-8	156
598	An atypical presentation of pulmonary air-leak syndrome and multisystem toxic epidermal necrolysis. 2014 , 49, E130-4	2
597	Paracetamol induced Stevens-Johnson syndrome--toxic epidermal necrolysis overlap syndrome. 2014 , 53, 1042-4	16
596	Tear exchangeable limbal rigid contact lens for ocular sequelae resulting from Stevens-Johnson syndrome or toxic epidermal necrolysis. 2014 , 158, 983-93	22

595	[Severe drug-induced skin reactions. Stevens-Johnson syndrome and toxic epidermal necrolysis]. 2014 , 65, 415-23	5
594	Management of nonimmediate hypersensitivity reactions to drugs. 2014 , 34, 473-87, vii	16
593	Antiviral drug allergy. 2014 , 34, 645-62, ix	7
592	Retrospective review of Stevens-Johnson syndrome/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine. 2014 , 71, 941-7	119
591	A topical matter: toxic epidermal necrolysis. 2014 , 127, 931-2	3
590	Stevens-Johnson syndrome induced by the cross-reactivity between teicoplanin and vancomycin. 2014 , 39, 442-5	11
589	Severe flucloxacillin-induced acute generalized exanthematous pustulosis (AGEP), with toxic epidermal necrolysis (TEN)-like features: does overlap between AGEP and TEN exist? Clinical report and review of the literature. 2014 , 171, 1539-45	20
588	Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. 2014 , 40, 1707-12	18
587	TNF- α is a useful predictor of human herpesvirus-6 reactivation and indicator of the disease process in drug-induced hypersensitivity syndrome (DIHS)/drug reaction with eosinophilia and systemic symptoms (DRESS). 2014 , 74, 177-9	11
586	An update on pediatric cutaneous drug eruptions. 2014 , 32, 516-23	11
585	Toxic epidermal necrolysis (TEN): the Chelsea and Westminster Hospital wound management algorithm. 2014 , 67, 1026-32	26
584	Hospital management and clinical factors associated with ophthalmic involvement in toxic epidermal necrolysis. 2014 , 40, 903-8	3
583	Hypersensitivity to antiepileptic drugs. 2014 , 34, 633-43, ix	14
582	Urethral discharge and mucocutaneous involvement. 2014 , 214, e91-2	2
581	SJS/TEN overlap associated with lomefloxacin: case report and molecular typing studies. 2014 , 229, 319-23	2
580	Fatal case of cephalexin-induced toxic epidermal necrolysis. 2014 , 2, 2050313X14532250	0
579	A Suspected Case of Efavirenz-Induced Stevens-Johnson Syndrome. 2015 , 2, 15	4
578	Severe drug-induced skin reactions: clinical features, diagnosis, etiology, and therapy. 2015 , 13, 625-45	32

577	Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis. 2015 , 42, 768-77	40
576	Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. 2015 , 16, 374	2
575	Drugs causing severe ocular surface involvements in Japanese patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 2015 , 64, 379-81	10
574	Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. 2015 , 173, 1224-31	20
573	Occupational toxic epidermal necrolysis associated with dalbergia cochinchinensis: a retrospective comparative study of eight cases in China. 2015 , 54, 1435-41	3
572	Human herpes virus reactivations and dynamic cytokine profiles in patients with cutaneous adverse drug reactions --a prospective comparative study. 2015 , 70, 568-75	34
571	Epidermal necrolysis: 60 years of errors and advances. 2015 , 173, 1250-4	44
570	A clinicotherapeutic analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis with an emphasis on the predictive value and accuracy of SCORE of Toxic Epidermal Necrolysis. 2015 , 54, e18-26	15
569	Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2015 , 160, 228-237.e2	77
568	Lamotrigine-induced severe cutaneous adverse reaction: Update data from 1999-2014. 2015 , 22, 1005-11	19
567	Recent advances of pharmacogenomics in severe cutaneous adverse reactions: immune and nonimmune mechanisms. 2015 , 5, 59-67	22
566	Schwere arzneimittelinduzierte Hautreaktionen: Klinik, Diagnostik, Biologie und Therapie. 2015 , 13, 625-645	27
565	Cutaneous drug rashes. 2015 , 76, C166-9	1
564	The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome. 2015 , 122, 254-64	45
563	IKZF1, a new susceptibility gene for cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis with severe mucosal involvement. 2015 , 135, 1538-45.e17	50
562	Stevens-Johnson syndrome and toxic epidermal necrolysis: a 20-year single-center experience. 2015 , 54, 978-84	26
561	Mycoplasma pneumoniae-induced rash and mucositis as a syndrome distinct from Stevens-Johnson syndrome and erythema multiforme: a systematic review. 2015 , 72, 239-45	178
560	Mixed signals: toxic epidermal necrolysis. 2015 , 128, 254-6	0

559	Lack of cross-toxicity between isoniazid and ethionamide in severe cutaneous adverse drug reactions: a series of 25 consecutive confirmed cases. 2015 , 70, 2648-51	11
558	Toxic epidermal necrolysis secondary to Mycoplasma pneumoniae and herpes simplex virus infection. 2015 , 48, 37-43	1
557	[Ophthalmic manifestations after Lyell and Stevens-Johnson syndromes]. 2015 , 142, 393-8	2
556	Clinical and microscopic characteristics of canine toxic epidermal necrolysis. 2015 , 52, 321-30	11
555	Risk of toxic epidermal necrolysis and Stevens-Johnson syndrome associated with benzodiazepines: a population-based cohort study. 2015 , 71, 759-766	12
554	A 15-year review of pediatric toxic epidermal necrolysis. 2015 , 36, 130-6	29
553	Independent strong association of HLA-A*02:06 and HLA-B*44:03 with cold medicine-related Stevens-Johnson syndrome with severe mucosal involvement. 2014 , 4, 4862	67
552	Nonbullous Erythema Multiforme in Hospitalized Children: A 10-Year Survey. 2015 , 32, 701-3	7
551	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Update. 2015 , 16, 475-93	101
550	Outbreak of Mycoplasma pneumoniae-Associated Stevens-Johnson Syndrome. 2015 , 136, e386-94	55
549	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. 2015 , 172, 400-5	18
548	Stevens-Johnson syndrome and toxic epidermal necrolysis: an update on pharmacogenetics studies in drug-induced severe skin reaction. 2015 , 16, 1989-2002	10
547	Diclofenac sodium induced Stevens-Johnson syndrome in a hospitalized patient during treatment of splenic injury and mandibular fracture. 2015 , 27, 29-32	1
546	Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin. 2015 , 74, 2157-64	132
545	Clinical features of and genetic predisposition to drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a single Korean tertiary institution patients-investigating the relation between the HLA -B*4403 allele and lamotrigine. 2015 , 71, 35-41	17
544	Immunological response in Stevens-Johnson syndrome and toxic epidermal necrolysis. 2015 , 42, 42-8	22
543	Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies. 2015 , 54, 108-15	62
542	Toxic epidermal necrolysis. 2016 , 5,	14

541	Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2016 , 36, 174	3
540	Ibuprofen induced Stevens-Johnson syndrome - toxic epidermal necrolysis in Nepal. 2016 , 6, 70-3	17
539	Toxic epidermal necrolysis and concurrent granulomatosis with polyangiitis (Wegener's granulomatosis). Management of a rare case and review of the literature. 2016 , 2, 2059513116642129	
538	HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs. 2016 , 57, 118-26	37
537	Incidence of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Nationwide Population-Based Study Using National Health Insurance Database in Korea. 2016 , 11, e0165933	57
536	U.K. guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. 2016 , 174, 1194-227	143
535	Drug-induced liver injury associated with Stevens-Johnson syndrome/toxic epidermal necrolysis: Patient characteristics, causes, and outcome in 36 cases. 2016 , 63, 993-9	44
534	Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. 2016 , 175, 150-6	31
533	Stevens-Johnson syndrome/toxic epidermal necrolysis caused by cefadroxil in a cat. 2016 , 2, 2055116916653616	
532	Ocular manifestations of Stevens-Johnson syndrome and their management. 2016 , 27, 522-529	37
531	Administrative and Survey Data: Potential and Pitfalls. 2016 , 136, 2122-2124	7
530	Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions. 2016 , 136, 1373-1381	57
529	Ocular Manifestations of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children. 2016 , 166, 68-75	43
528	A case of Stevens-Johnson syndrome with gross hematuria. 2016 , 2, 65-66	1
527	In reply: Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. 2016 , 121, 681-2	
526	[Severe cutaneous drug reactions to misused griseofulvin: 2 cases]. 2016 , 143, 219-22	2
525	Morbidity and Mortality of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in United States Adults. 2016 , 136, 1387-1397	142
524	Mycoplasma pneumoniae-Induced Mucocutaneous Rash: A New Syndrome Distinct from Erythema Multiforme? Report of a New Case and Review of the Literature. 2016 , 107, e47-51	10

523	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. 2016 , 129, 1221-1225	47
522	Increased risk of strontium ranelate-related SJS/TEN is associated with HLA. 2016 , 27, 2577-83	11
521	Presumed phenobarbital-induced Stevens-Johnson syndrome in a 4-year-old female Great Dane. 2016 , 36, 242-246	2
520	Evaluation of Lymphocyte Transformation Test Results in Patients with Delayed Hypersensitivity Reactions following the Use of Anticonvulsant Drugs. 2016 , 170, 158-62	22
519	A retrospective analysis of Stevens-Johnson syndrome/toxic epidermal necrolysis treated with corticosteroids. 2016 , 55, 1408-1413	21
518	[Childhood postinfectious erythema multiforme]. 2016 , 23, 1184-1190	2
517	Toxic epidermal necrolysis caused by acetaminophen featuring almost 100% skin detachment: Acetaminophen is associated with a risk of severe cutaneous adverse reactions. 2016 , 43, 321-4	9
516	Re-evaluation of 'drug-induced' erythema multiforme in the medical literature. 2016 , 175, 650-1	7
515	Drug induced exfoliative dermatitis: state of the art. 2016 , 14, 9	10
514	HLA and Delayed Drug-Induced Hypersensitivity. 2016 , 170, 163-79	25
513	The use of porcine xenografts in patients with toxic epidermal necrolysis. 2016 , 42, 1728-1733	8
512	Das Dokumentationszentrum schwerer Hautreaktionen. 2016 , 403-416	0
511	Mycoplasma pneumoniae-Induced Mucocutaneous Rash: A New Syndrome Distinct from Erythema Multiforme? Report of a New Case and Review of the Literature. 2016 , 107, e47-e51	3
510	[Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN) related to insecticide: Second case in the literature and potential implications]. 2016 , 117, 176-82	1
509	Successful Combination Therapy Including Plasma Exchange for Severe Toxic Epidermal Necrolysis. 2016 , 17, 232-237	0
508	Two cases of overlap severe cutaneous adverse reactions to benznidazole treatment for asymptomatic Chagas disease in a nonendemic country. 2016 , 175, 604-7	13
507	Longitudinal analysis of antibody profiles against plakins in severe drug eruptions: emphasis on correlation with tissue damage in drug-induced hypersensitivity syndrome and drug reaction with eosinophilia and systemic symptoms. 2016 , 175, 944-952	13
506	UK guidelines for the management of Stevens-Johnson syndrome/toxic epidermal necrolysis in adults 2016. 2016 , 69, e119-e153	46

505	Predicting Mechanical Ventilation and Mortality: Early and Late Indicators in Steven-Johnson Syndrome and Toxic Epidermal Necrolysis. 2016 , 37, e47-55	5
504	Analysis of Ocular Manifestation and Genetic Association of Allopurinol-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in South Korea. 2016 , 35, 199-204	13
503	Severe cutaneous adverse drug reactions. 2016 , 43, 758-66	111
502	Burn unit care of Stevens Johnson syndrome/toxic epidermal necrolysis: A survey. 2016 , 42, 830-5	20
501	Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?. 2016 , 107, 23-33	6
500	Adverse cutaneous drug eruptions: current understanding. 2016 , 38, 75-86	82
499	Erythema Multiforme in Children and Mycoplasma pneumoniae Aetiology. 2016 , 20, 453-7	19
498	Oral erythema multiforme: trends and clinical findings of a large retrospective: European case series. 2016 , 121, 681	2
497	Indications for intubation and early tracheostomy in patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2016 , 211, 684-688.e1	12
496	Severe adverse drug reactions. 2016 , 16, 79-83	13
495	Severe Cutaneous Drug Reactions: Do Overlapping Forms Exist?. 2016 , 107, 23-33	
494	A decade of burn unit experience with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: Clinical pathological diagnosis and risk factor awareness. 2016 , 42, 836-43	18
493	Stevens-Johnson syndrome: The role of an ophthalmologist. 2016 , 61, 369-99	46
492	Oral ulcers and an unusual skin rash in a teenager. 2016 , 29, 54-6	1
491	Penicillins. 2016 , 591-611	0
490	Mucosal erosions as the presenting symptom in erythema multiforme: a case report. 2016 , 66, e222-4	2
489	Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome. 2016 , 65, 74-81	61
488	Adverse drug reactions and organ damage: The skin. 2016 , 28, 17-24	32

487	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis and Erythema Exsudativum Multiforme. 2016 , 183-193	1
486	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis--A Comprehensive Review and Guide to Therapy. I. Systemic Disease. 2016 , 14, 2-19	85
485	Stevens-Johnson syndrome after treatment with azithromycin: an uncommon culprit. 2016 , 34, 676.e1-3	14
484	Complications of Stevens-Johnson syndrome beyond the eye and skin. 2016 , 42, 20-27	38
483	HLA-B*59:01: a marker for Stevens-Johnson syndrome/toxic epidermal necrolysis caused by methazolamide in Han Chinese. 2016 , 16, 83-7	37
482	HIV-Associated Toxic Epidermal Necrolysis at San Francisco General Hospital. 2017 , 16, 37-41	6
481	Pediatric Erythema Multiforme in the Emergency Department: More Than "Just a Rash". 2017 , 33, 320-324	3
480	Toxic epidermal necrolysis: 13 years of experience in the management at a Department of Dermatology in China. 2017 , 36, 19-24	8
479	Variable levels of apoptotic signal-associated cytokines in the disease course of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2017 , 58, e61-e67	11
478	Comparison of severe drug eruptions in Japan between 2005-2009 and 2010-2014 based on data from the relief system of the Pharmaceuticals and Medical Devices Agency. 2017 , 44, e5-e6	3
477	Stevens-Johnson syndrome in childhood. 2017 , 92, 241-244	2
476	Adverse drug reactions. 2017 , 63, 49-53	2
475	Long-term complications of Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN): the spectrum of chronic problems in patients who survive an episode of SJS/TEN necessitates multidisciplinary follow-up. 2017 , 177, 924-935	71
474	Microbiological findings and antibacterial therapy in Stevens-Johnson syndrome/toxic epidermal necrolysis patients from a Swedish Burn Center. 2017 , 44, 420-432	9
473	Treatment of recurrent erythema multiforme with adalimumab as monotherapy. 2017 , 3, 95-97	9
472	Stevens-Johnson syndrome in childhood. 2017 , 92, 241-244	
471	Characterization of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Among Patients Admitted to Kenyatta National Hospital: A Retrospective Cross-Sectional Study. 2017 , 4, 79-85	10
470	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology--Thirty Years of Progress but Still Much to Be Done. 2017 , 137, 1004-1008	43

469	HLA-A*24:02 as a common risk factor for antiepileptic drug-induced cutaneous adverse reactions. 2017 , 88, 2183-2191	66
468	Methotrexate-induced epidermal necrosis: A case series of 24 patients. 2017 , 77, 247-255.e2	26
467	Severe Delayed Cutaneous and Systemic Reactions to Drugs: A Global Perspective on the Science and Art of Current Practice. 2017 , 5, 547-563	70
466	Rash Decisions: An Approach to Dangerous Rashes Based on Morphology. 2017 , 52, 457-471	6
465	Risk and association of HLA with oxcarbazepine-induced cutaneous adverse reactions in Asians. 2017 , 88, 78-86	83
464	The use of Biobrane for wound coverage in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2017 , 43, 1464-1472	9
463	Cyclosporine Use in Epidermal Necrolysis Is Associated with an Important Mortality Reduction: Evidence from Three Different Approaches. 2017 , 137, 2092-2100	81
462	Gout: An old disease in new perspective - A review. 2017 , 8, 495-511	200
461	Score of Toxic Epidermal Necrosis Predicts the Outcomes of Pediatric Epidermal Necrolysis. 2017 , 34, 433-437	16
460	Pustular erythema multiforme major associated with atypical pneumonia. 2017 , 31, e502-e503	1
459	Mucositis Secondary to Chlamydia pneumoniae Infection: Expanding the Mycoplasma pneumoniae-Induced Rash and Mucositis Concept. 2017 , 34, 465-472	25
458	Approach to Severe Cutaneous Adverse Drug Reactions. 2017 , 4, 201-221	2
457	Characterization of Children With Recurrent Episodes of Stevens Johnson Syndrome. 2017 , 6, e140-e143	17
456	Fever in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Pediatric Cases: Laboratory Work-up and Antibiotic Therapy. 2017 , 36, 513-515	17
455	Severe Cutaneous Adverse Drug Reactions in Pediatric Patients: A Multicenter Study. 2017 , 5, 757-763	42
454	Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. 2017 , 76, 811-817.e4	58
453	Genitourinary involvement and management in children with Stevens-Johnson syndrome and toxic epidermal necrolysis. 2017 , 13, 490.e1-490.e7	15
452	Interleukin-15 Is Associated with Severity and Mortality in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 2017 , 137, 1065-1073	64

451	Dapsone-induced severe cutaneous adverse drug reactions are strongly linked with HLA-B*13: 01 allele in the Thai population. 2017 , 27, 429-437	56
450	Severe Delayed Drug Reactions: Role of Genetics and Viral Infections. 2017 , 37, 785-815	20
449	SnapshotDx Quiz: October 2017. 2017 , 137, e179	
448	Eritema multiforme. 2017 , 51, 1-9	1
447	Serum IL-17 in patients with erythema multiforme or Stevens-Johnson syndrome/toxic epidermal necrolysis drug reaction, and correlation with disease severity. 2017 , 42, 868-873	1
446	[Severe cutaneous drug reactions in children]. 2017 , 68, 803-814	1
445	[Another 'last word' on Rowell's syndrome]. 2017 , 144, 247-249	
444	Oral health impacts of medications used to treat mental illness. 2017 , 223, 184-193	30
443	[Another 'last word' on Rowell's syndrome]. 2017 , 144, e1-e3	
442	A clinicoetiological analysis of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis treated at Sohag University Hospital, Egypt. 2017 , 14, 37-44	3
441	Cutaneous adverse drug reactions: Kids are not just little people. 2017 , 35, 566-582	8
440	Delayed-type hypersensitivity to oral and parenteral drugs. 2017 , 15, 1111-1132	2
439	Burn Center Care of Patients with Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2017 , 44, 583-595	11
438	Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study. 2017 , 17, 65	5
437	Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 - 2015. 2017 , 12, 14	23
436	Patch testing - a valuable tool for investigating non-immediate cutaneous adverse drug reactions to antibiotics. 2017 , 31, 280-287	45
435	Apoptosis as a Mechanism for Keratinocyte Death in Canine Toxic Epidermal Necrolysis. 2017 , 54, 249-253	5
434	Serum TARC levels are strongly correlated with blood eosinophil count in patients with drug eruptions. 2017 , 66, 116-122	16

433	Cyclosporine treatment for Stevens-Johnson syndrome/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center. 2017 , 76, 106-113	51
432	A review of toxic epidermal necrolysis management in Japan. 2017 , 66, 36-41	23
431	Significant HLA class I type associations with aromatic antiepileptic drug (AED)-induced SJS/TEN are different from those found for the same AED-induced DRESS in the Spanish population. 2017 , 115, 168-178	39
430	Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis in adults. 2017 , 56, e78-e79	1
429	Oxcarbazepine-induced Stevens-Johnson syndrome: a pediatric case report. 2017 , 2017, omx028	2
428	Retrospective review of paediatric case reports of Stevens-Johnson syndrome and toxic epidermal necrolysis with lamotrigine from an international pharmacovigilance database. 2017 , 1, e000039	9
427	Spättypreaktionen auf oral und parenteral verabreichte Arzneimittel. 2017 , 15, 1111-1134	3
426	Factors Contributing to Long-Term Severe Visual Impairment in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2017 , 2017, 2087578	10
425	Management of the cutaneous adverse effects of antimelanoma therapy. 2017 , 4, 187-202	4
424	Treatments for Severe Cutaneous Adverse Reactions. 2017 , 2017, 1503709	27
423	[Targeting the skin - erythema multiforme in dogs and cats]. 2017 , 45, 352-356	
422	Retrospective Analysis of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in 88 Chinese Patients. 2017 , 130, 1062-1068	13
421	Stevens-Johnson syndrome and abuse of anabolic steroids. 2017 , 43, 57-60	4
420	Pharmacogenetics of adverse reactions to antiepileptic drugs. 2018 , 33, 165-176	15
419	Risks associated with lamotrigine prescription: a review and personal observations. 2018 , 26, 640-642	6
418	Pediatric Lip Adhesion Following Bullous Erythema Multiforme and Review of Similar Oral Complications. 2018 , 22, 427-430	1
417	The measurement of drug-induced interferon γ -releasing cells and lymphocyte proliferation in severe cutaneous adverse reactions. 2018 , 32, 992-998	17
416	Nursing care of a boy seriously infected with Steven-Johnson syndrome after treatment with azithromycin: A case report and literature review. 2018 , 97, e9112	12

415	Histopathology of Cutaneous Inflammatory Disorders in Children. 2018 , 21, 115-149	2
414	Toxic Epidermal Necrolysis: A Dermatologic Emergency and the Role of the Oral and Maxillofacial Surgeon. 2018 , 76, 1688-1694	3
413	From HSV infection to erythema multiforme through autoimmune crossreactivity. 2018 , 17, 576-581	10
412	Ethosuximide-induced Stevens-Johnson syndrome: Beneficial effect of early intervention with high-dose corticosteroid therapy. 2018 , 45, 592-595	4
411	Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients-Exposed/Unexposed and Propensity Score-Matched Analyses. 2018 , 138, 1293-1300	25
410	Adverse Drug Reactions. 2018 , 519-576	0
409	Current Perspectives on Erythema Multiforme. 2018 , 54, 177-184	54
408	Management of severe drug reactions: a retrospective monocentric analysis. 2018 , 27, 49-55	
407	Pharmacogenetics of adverse reactions to antiepileptic drugs. 2018 , 33, 165-176	1
406	Specific association of the rs6500265 and rs9933632 single-nucleotide polymorphisms in Japanese patients with antipyretic analgesic-related Stevens-Johnson syndrome and toxic epidermal necrolysis with severe ocular involvements. 2018 , 28, 95-98	0
405	[Acute life-threatening drug reactions of the skin]. 2018 , 69, 364-375	0
404	[Factors associated with the severity of acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis in sub-Saharan Africa]. 2018 , 145, 245-249	2
403	The Function of HLA-B*13:01 Involved in the Pathomechanism of Dapsone-Induced Severe Cutaneous Adverse Reactions. 2018 , 138, 1546-1554	34
402	The Frequency and Clinical Features of Hypersensitivity Reactions to Antiepileptic Drugs in Children: A Prospective Study. 2018 , 6, 2043-2050	12
401	[Severe skin reactions due to new medications]. 2018 , 69, 278-289	0
400	Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. 2018 , 73, 221-229	23
399	Severe sequelae of erythema multiforme: three cases. 2018 , 32, e34-e36	7
398	Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. 2018 , 6, 700-702.e2	7

397	Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience. 2018 , 44, 603-611	20
396	Drug Allergy. 2018 , 19-26	4
395	Cutaneous Reactions to Drugs. 2018 , 53-72	3
394	Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2018 , 54, 147-176	127
393	Hospitalization and outcomes attributed to epidermal necrolysis in the United States: predictors of mortality. 2018 , 32, e47-e50	1
392	Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. 2018 ,	2
391	AGEP overlap induced by hydroxychloroquine: a case report and literature review. 2018 , 8, 360-362	6
390	Drug Allergy and Adverse Drug Reactions. 2018 , 1-14	
389	Life-Threatening Dermatological Emergencies. 2018 , 875-891	0
388	Síndromes de Stevens-Johnson y de Lyell. 2018 , 52, 1-9	
387	Life-threatening dermatoses: Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. Impact on the Spanish public health system (2010-2015). 2018 , 13, e0198582	9
386	An Updated Review of the Molecular Mechanisms in Drug Hypersensitivity. 2018 , 2018, 6431694	68
385	Schwere kutane Arzneimittelreaktionen. 2018 , 625-632	
384	Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multicenter Retrospective Study of 377 Adult Patients from the United States. 2018 , 138, 2315-2321	58
383	Care in patients with epidermal necrolysis in burn units. A nursing perspective. 2018 , 44, 1962-1972	7
382	Hypomethylation Is Associated with Allopurinol-Induced Severe Cutaneous Adverse Reactions during Disease Onset Period: A Multicenter Retrospective Case-Control Clinical Study in Han Chinese. 2017 , 8, 923	6
381	Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. 2018 , 27, 1042-1050	10
380	Management and outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients admitted to Kenyatta National Hospital. 2018 , 34, 444-450	

379	Retrospektive, monozentrische Analyse des Managements schwerer Arzneimittelreaktionen. 2018 , 27, 26-33	
378	Monocytes are involved in the balance between regulatory T cells and Th17 cells in severe drug eruptions. 2018 , 48, 1453-1463	17
377	Procalcitonin as a diagnostic indicator for systemic bacterial infections in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 2018 , 45, 989-993	4
376	Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis. 2018 , 60, 697-702	14
375	Analysis of HLA-B Allelic Variation and IFN- γ ELISpot Responses in Patients with Severe Cutaneous Adverse Reactions Associated with Drugs. 2019 , 7, 219-227.e4	21
374	Rashes and other hypersensitivity reactions associated with antiepileptic drugs: A review of current literature. 2019 , 71, 270-278	9
373	Drug-induced severe cutaneous adverse reactions: Determine the cause and prevention. 2019 , 123, 483-487	13
372	Distinguishing Stevens-Johnson syndrome/toxic epidermal necrolysis from clinical mimickers during inpatient dermatologic consultation-A retrospective chart review. 2019 , 81, 749-757	13
371	Galectin-7 as a potential biomarker of Stevens-Johnson syndrome/toxic epidermal necrolysis: identification by targeted proteomics using causative drug-exposed peripheral blood cells. 2019 , 7, 2894-2897.e7	8
370	Carbonic anhydrase inhibitor-induced Stevens-Johnson syndrome/toxic epidermal necrolysis leads to extensive cutaneous involvement. 2019 , 7, 2851-2853.e2	5
369	Outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in HIV-infected patients when using systemic steroids and/or intravenous immunoglobulins in Pietermaritzburg, South Africa. 2019 , 20, 944	4
368	Risk factors and diagnostic markers of bacteremia in Stevens-Johnson syndrome and toxic epidermal necrolysis: A cohort study of 176 patients. 2019 , 81, 686-693	13
367	Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 2019 , 208, 331-341	22
366	Stevens-Johnson syndrome associated with radiation recall dermatitis in a patient treated with immune checkpoint inhibitor. 2019 , 46, e434-e436	5
365	Ocular manifestations in patients with Stevens-Johnson syndrome in Malawi-review of the literature illustrated by clinical cases. 2019 , 257, 2343-2348	3
364	Unique Clinical Characteristics and Prognosis of Allopurinol-Induced Severe Cutaneous Adverse Reactions. 2019 , 7, 2739-2749.e3	7
363	Unusual oral findings of the toxic epidermal necrolysis in an HIV-infected patient: a case report. 2019 , 23, 363-367	0
362	Severe skin reactions: clinical picture, epidemiology, etiology, pathogenesis, and treatment. 2019 , 28, 311-326	3

361	Drug-induced liver injury. 2019 , 5, 58	148
360	Nursing problems in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome in a Dutch burn centre: A 30-year retrospective study. 2019 , 45, 1625-1633	0
359	Life-Threatening Extrarenal Manifestations in an Infant with Atypical Hemolytic Uremic Syndrome Caused by a Complement 3-Gene Mutation. 2019 , 44, 1300-1305	0
358	Allopurinol-Induced Toxic Epidermal Necrolysis. 2019 , 6, 8	1
357	Hypersensitivity and Cardiovascular Risks Related to Allopurinol and Febuxostat Therapy in Asians: A Population-Based Cohort Study and Meta-Analysis. 2019 , 106, 391-401	17
356	Phenotypes of Severe Cutaneous Adverse Reactions Caused by Nonsteroidal Anti-inflammatory Drugs. 2019 , 11, 212-221	11
355	Drug reaction with eosinophilia and systemic symptoms syndrome after total knee arthroplasty infection and placement of antibiotic spacer. 2019 , 5, 148-151	5
354	Drug Allergy and Adverse Drug Reactions. 2019 , 491-504	
353	Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database. 2019 , 44, 775-779	9
352	Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective descriptive study. 2019 , 58, 1293-1299	10
351	Mechanisms of Severe Cutaneous Adverse Reactions: Recent Advances. 2019 , 42, 973-992	33
350	Association of Early Systemic Corticosteroid Therapy with Mortality in Patients with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis: A Retrospective Cohort Study Using a Nationwide Claims Database. 2019 , 20, 579-592	9
349	Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10. 2019 , 155, 448-454	32
348	Stevens-Johnson syndrome and toxic epidermal necrolysis cases treated at our hospital over the past 10 years. 2019 , 2, 25-30	1
347	Oral Signs of Vesiculobullous and Autoimmune Disease. 2019 , 113-144	
346	Bronchiolitis obliterans as a long-term sequela of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. 2019 , 44, 897-902	7
345	A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016. 2019 , 58, 1141-1147	8
344	Ocular and Mucocutaneous Sequelae among Survivors of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Togo. 2019 , 2019, 4917024	5

343	White and Red Lesions of the Oral Mucosa. 2019 , 1207-1248	1
342	Pediatric Oral Medicine. 2019 , 1641-1718	1
341	Epidermal necrolysis: SCORTEN performance in AIDS and non-AIDS patients. 2019 , 94, 17-23	7
340	Phenotypes and Natural Evolution of Drug Hypersensitivity. 2019 , 6, 27-41	2
339	Multistep Grading System for Evaluation of Chronic Ocular Sequelae in Patients With Stevens-Johnson Syndrome. 2019 , 203, 69-77	7
338	Un lupus fythmateux systmique se prsentant sous la forme dâIn syndrome de Stevens-Johnson. 2019 , 59, 418-420	
337	A Review of the Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2019 , 41, 56-64	9
336	Toxic Epidermal Necrolysis Induced by Leflunomide in a Patient With Rheumatoid Arthritis. 2019 ,	2
335	Erythema Multiforme, StevensâJohnson Syndrome and Toxic Epidermal Necrolysis. 2019 , 777-784	1
334	An atypical presentation of toxic epidermal necrolysis without mucosal involvement.. 2022 , 78, 106-108	0
333	Characteristics of meibomian gland dysfunction in patients with Stevens-Johnson syndrome. 2019 , 98, e16155	5
332	Making a diagnosis in severe cutaneous drug hypersensitivity reactions. 2019 , 19, 283-293	22
331	Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: a Review and Update. 2019 , 8, 219-233	3
330	Schwere Hautreaktionen: klinisches Bild, Epidemiologie, Biologie, Pathogenese und Therapie. 2019 , 28, 16-34	0
329	Deep Inferior Epigastric Artery Perforator Flap Breast Reconstruction in a Patient with a History of Toxic Epidermal Necrosis. 2019 , 7, e2190	
328	A Case Study of Toxic Epidermal Necrolysis. 2019 , 8, 74-78	
327	Meropenem-induced Stevens-Johnson syndrome/toxic epidermal necrolysis in a patient with known type IV penicillin hypersensitivity. 2019 , 12,	4
326	Ocular, Aural, and Oral Manifestations of Lupus. 2019 , 556-565	1

325	Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). 2019 , 87-104	1
324	Natural compounds with xanthine oxidase inhibitory activity: A review. 2019 , 93, 387-418	45
323	Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality. 2019 , 30, 718-723	8
322	Serum and blister-fluid elevation and decreased epidermal content of high-mobility group box 1 protein in drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. 2019 , 181, 166-174	6
321	Introduction: Classification, Terminology, Epidemiology, and Etiology of Cutaneous Adverse Drug Reactions. 2019 , 3-20	0
320	Dermatologic Conditions of the Early Post-Transplant Period in Hematopoietic Stem Cell Transplant Recipients. 2019 , 20, 55-73	2
319	The rash that presents as target lesions. 2019 , 37, 148-158	3
318	Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study. 2019 , 75, 237-246	8
317	HLA Alleles and CYP2C9*3 as Predictors of Phenytoin Hypersensitivity in East Asians. 2019 , 105, 476-485	32
316	The Medication Risk of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Asians: The Major Drug Causality and Comparison With the US FDA Label. 2019 , 105, 112-120	29
315	Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. 2020 , 31, 66-73	20
314	HLA-B*51:01 and CYP2C9*3 Are Risk Factors for Phenytoin-Induced Eruption in the Japanese Population: Analysis of Data From the Biobank Japan Project. 2020 , 107, 1170-1178	8
313	Treatment for oral lesions in pediatric patients with Stevens-Johnson's syndrome: A case report and literature review. 2020 , 30, 489-496	3
312	Characteristics of cutaneous adverse drug reactions caused by triple-combination drug therapy used for Helicobacter pylori eradication. 2020 , 47, 277-282	0
311	Erythema multiforme, Stevens Johnson syndrome, and toxic epidermal necrolysis reported after vaccination, 1999-2017. 2020 , 38, 1746-1752	13
310	Adverse Reactions Associated with Penicillins, Carbapenems, Monobactams, and Clindamycin: A Retrospective Population-based Study. 2020 , 8, 1302-1313.e2	10
309	The psychological impact of Stevens-Johnson syndrome and toxic epidermal necrolysis on patients' lives: a Critically Appraised Topic. 2020 , 183, 452-461	7
308	Accuracy of SCORTEN to predict the prognosis of Stevens-Johnson syndrome/toxic epidermal necrolysis: a systematic review and meta-analysis. 2020 , 34, 2066-2077	14

307	Confusion in determination of two types of cutaneous adverse reactions to drugs, maculopapular eruption and erythema multiforme, among the experts: A proposal of standardized terminology. 2020 , 47, 169-173	
306	Pembrolizumab-Induced Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis in a Patient With Metastatic Cervical Squamous Cell Carcinoma: A Case Report. 2020 , 42, 292-296	9
305	-Induced Rash and Mucositis in a Previously Healthy Man: A Case Report and Brief Review of the Literature. 2020 , 7, ofaa437	2
304	Assessment and Comparison of Performance of ABCD-10 and SCORTEN in Prognostication of Epidermal Necrolysis. 2020 , 156, 1294-1299	7
303	Recurrent Stevens-Johnson syndrome in a patient with systemic lupus erythematosus: a case report. 2020 , 48, 300060520964348	
302	Ocular manifestations of mycoplasma-induced rash and mucositis. 2020 , 24, 249-251	2
301	HLA genotypes and cold medicine-induced Stevens-Johnson syndrome/toxic epidermal necrolysis with severe ocular complications: a systematic review and meta-analysis. 2020 , 10, 10589	7
300	Pharmacogenomics for Primary Care: An Overview. 2020 , 11,	6
299	The use of biostatic human amnion and platelet-rich plasma in topical treatment of toxic epidermal necrolysis-A case report. 2021 , 20, 2887-2893	1
298	The nationwide epidemiological survey of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan, 2016-2018. 2020 , 100, 175-182	7
297	Predictive biomarkers for the progression of ocular complications in chronic Stevens-Johnson syndrome and toxic Eeidermal necrolysis. 2020 , 10, 18922	7
296	Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database. 2020 , 61, 1979-1989	8
295	Analysis of severity and preventability in patients of-Toxic epidermal necrolysis-A case series. 2020 , 8, 2452-2456	0
294	Severe cutaneous adverse drug reactions: Incidence, clinical patterns, causative drugs and modalities of treatment in Assiut University Hospital, Upper Egypt. 2020 , 33, e14176	2
293	HLA-B*58: 01 association in allopurinol-induced severe cutaneous adverse reactions: the implication of ethnicity and clinical phenotypes in multiethnic Malaysia. 2020 , 30, 153-160	1
292	Accuracy of SCORTEN and ABCD-10 to predict mortality and the influence of renal function in Stevens-Johnson syndrome/toxic epidermal necrolysis. 2020 , 47, 1182-1186	5
291	Drug induced liver injury: an update. 2020 , 94, 3381-3407	40
290	Approaching Target and Targetoid Eruptions in Inpatient Dermatology. 2020 , 9, 210-219	

289	Toxic epidermal necrolysis syndrome induced by tigecycline: a case report. 2020 , 48, 300060520922416	0
288	Incidence of Epidermal Necrolysis: Results of the German Registry. 2020 , 140, 2525-2527	2
287	Cancer immunotherapy and toxic epidermal necrolysis. 2020 , 10, 314-315	1
286	Ventilatory support in Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. 2020 , 1-6	0
285	Erythema multiforme, Stevens-Johnson syndrome/toxic epidermal necrolysis - diagnosis and treatment. 2020 , 18, 547-553	6
284	Clinical trial to evaluate the therapeutic benefits of limbal-supported contact lens wear for ocular sequelae due to Stevens-Johnson syndrome/toxic epidermal necrolysis. 2020 , 43, 535-542	4
283	Erythema exsudativum multiforme, Stevens-Johnson-Syndrom/toxische epidermale Nekrolyse â Diagnostik und Therapie. 2020 , 18, 547-553	3
282	Multidisciplinary care in Stevens-Johnson syndrome. 2020 , 11, 2040622319894469	17
281	General characteristics, economic burden, causative drugs and medical errors associated with medical damage litigation involving severe cutaneous adverse drug reactions in China. 2020 , 45, 1087-1097	0
280	Stevens-Johnson syndrome and toxic epidermal necrolysis: risk factors, causality assessment and potential prevention strategies. 2020 , 16, 373-387	7
279	Clinical and pathogenic aspects of the severe cutaneous adverse reaction epidermal necrolysis (EN). 2020 , 34, 1957-1971	10
278	Stevens-Johnson Syndrome-Like Reaction After Exposure to Pembrolizumab and Recombinant Zoster Vaccine in a Patient With Metastatic Lung Cancer. 2020 , 8, 2324709620914796	6
277	Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017. 2020 , 11, 2042098620905998	9
276	Erythema Multiforme Major in a Dog Treated with Intravenous Human Immunoglobulin and Immunosuppressive Therapy. 2020 , 56, 133-138	1
275	Adverse cutaneous reactions to chemotherapeutic drugs. 2020 , 38, 712-728	4
274	Drug hypersensitivity reactions in Asia: regional issues and challenges. 2020 , 10, e8	3
273	Association of HLA-A*11:01 with Sulfonamide-Related Severe Cutaneous Adverse Reactions in Japanese Patients. 2020 , 140, 1659-1662.e6	7
272	DRESS syndrome after lamotrigine and valproic acid use in a bipolar patient: a case report. 2020 , 34, 160-163	0

271	Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis. 2020 , 18, 517-522	17
270	Acute pancreatic injuries: A complication of Stevens-Johnson syndrome/toxic epidermal necrolysis associated with cytotoxic immunocell activation. 2021 , 84, 644-653	0
269	Management of oral medicine emergencies during COVID-19: A study to develop practise guidelines. 2021 , 16, 493-500	5
268	Cutaneous Drug Reactions With Systemic Features. 2021 , 743-752.e4	
267	Intensive care needs and long-term outcome of pediatric toxic epidermal necrolysis - A 10-year experience. 2021 , 60, 44-52	0
266	Whole genome sequencing identifies genetic variants associated with co-trimoxazole hypersensitivity in Asians. 2021 , 147, 1402-1412	17
265	A Nationwide Study of Severe Cutaneous Adverse Reactions Based on the Multicenter Registry in Korea. 2021 , 9, 929-936.e7	6
264	The risk of anti-osteoporotic agent-induced severe cutaneous adverse drug reactions and their association with HLA. 2021 , 35, 712-720	5
263	Differences between Stevens-Johnson syndrome versus toxic epidermal necrolysis. 2021 , 60, 53-59	1
262	Investigating the association of Lamotrigine and Phenytoin-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis with HLA-B*1502 in Iranian population. 2021 , 30, 284-287	1
261	Mortality and risk factors on admission in toxic epidermal necrolysis: A cohort study of 59 patients. 2021 , 70, 229-234	4
260	Sifting through the history of the nosology of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis and its clinicopathological relevance. 2021 , 60, 110-112	1
259	Carbamazepine-induced Stevens-Johnson syndrome in a patient with history of methotrexate-induced mast cell activation syndrome. 2021 , 9, 256-259	1
258	When is a rash not a rash? A guide to recognition and treatment of paediatric dermatological emergencies. 2021 , 31, 46-54	0
257	Treating toxic epidermal necrolysis with systemic immunomodulating therapies: A systematic review and network meta-analysis. 2021 , 84, 390-397	20
256	Levamisole induced toxic epidermal necrolysis: A case report. 2021 , 87, 1574-1577	2
255	Macules or papules? No small matter!. 2020 ,	
254	Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers. 2021 , 39, 785-795	1

253	The Role of IL-13, IL-15 and Granulysin in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. 2021 , 27, 1076029620950831	2
252	Lichenoid dermatoses involving the vulva: A clinical-pathologic correlation. 2021 , 38, 3-18	2
251	Dermatology. 2021 , 451-469	
250	Severe Cutaneous Adverse Reactions to Anti-tuberculosis Drugs in Korean Patients. 2021 , 13, 245-255	3
249	Clonal expansion of CD4CD8 T cells in an adult patient with Mycoplasma pneumoniae-associated Erythema multiforme majus. 2021 , 17, 17	1
248	[Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis]. 2021 , 118, 519-532	0
247	Stevens Johnson syndrome: A review of a vision and life-threatening mucocutaneous disease including histopathology with updates on pathogenesis and genetic risk factors. 2021 , 36, 270-281	0
246	Corneal ectasia with Stevens-Johnson syndrome. 2021 , 104, 535-537	2
245	Evaluation of drug patch tests in children. 2021 , 42, 167-174	1
244	Implementation of Pharmacogenomic Information on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2021 , 8, 644154	0
243	Bronchiolitis obliterans following toxic epidermal necrolysis: a case report. 2021 , 15, 159	0
242	Cohort study of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis in China: evaluation of risk models and new predictor of pulmonary consolidation on computed tomography. 2021 , 15, 585-593	0
241	Immune checkpoint inhibitor-related epidermal necrolysis: A rare condition with poor prognosis. 2021 , 145, 194-196	3
240	Case Report: Wound Closure Acceleration in a Patient With Toxic Epidermal Necrolysis Using a Lyophilised Amniotic Membrane. 2021 , 9, 649317	1
239	Rare Diseases of the Oral Cavity, Neck, and Pharynx. 2021 , 100, S1-S24	
238	Prevalence of Clinical Spectrum of Cutaneous Adverse Drug Reactions in Patients Presenting at a Tertiary Care Hospital in Pakistan. 2021 , 13, e14568	1
237	Mycoplasma-induced Stevens-Johnson syndrome/toxic epidermal necrolysis: Case-control analysis of a cohort managed in a specialized center. 2021 ,	0
236	Drug induced oral erythema multiforme: Case report. 2021 , 100, e22387	2

235	Comparison of effectiveness of interventions in reducing mortality in patients of toxic epidermal necrolysis: A network meta-analysis. 2021 , 87, 628-644	2
234	Erythema Multiforme Attributable to Herpes Simplex Virus: Clinical Aspects and Treatment. 2021 , 2021, 6692495	1
233	Heater Integrated Lab-on-a-Chip Device for Rapid HLA Alleles Amplification towards Prevention of Drug Hypersensitivity. 2021 , 21,	2
232	Blistering severe cutaneous adverse reactions in children: proposal for paediatric-focused clinical criteria. 2021 , 185, 447-449	3
231	Neutrophil:lymphocyte ratio is associated with disease severity and mortality in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis. 2021 , 48, 1394-1400	1
230	Granulysin-Based Lymphocyte Activation Test for Evaluating Drug Causality in Antiepileptics-Induced Severe Cutaneous Adverse Reactions. 2021 , 141, 1461-1472.e10	4
229	An EAACI Task Force report on allergy to beta-lactams in children: Clinical entities and diagnostic procedures. 2021 , 32, 1426-1436	2
228	Capecitabine induced Steven-Johnson syndrome: A rare case report. 2022 , 28, 250-254	0
227	Physical and Psychological Recovery Following Toxic Epidermal Necrolysis: A Patient Survey. 2021 , 42, 1227-1231	
226	Chemokines in Severe Cutaneous Adverse Reactions (SCARs). 2021 , 11,	0
225	Neutrophils initiate and exacerbate Stevens-Johnson syndrome and toxic epidermal necrolysis. 2021 , 13,	1
224	A 7-year-old boy with toxic epidermal necrolysis, heart failure, and sepsis treated with the guidance of invasive hemodynamic monitoring: A case report. 2021 , 9, e04430	0
223	HLA-B*58:01 screening to prevent allopurinol-induced severe cutaneous adverse reactions in Chinese patients with chronic kidney disease. 2021 , 1	2
222	Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan. 2021 , 41, 2671-2680	2
221	Japan: Diagnosis and Management of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications. 2021 , 8, 657327	0
220	Target and targetoid lesions in dermatology. 2021 , 1-5	0
219	Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. 2021 , 35, 2051-2058	1
218	Treating Through Drug-Associated Exanthems in Drug Allergy Management: Current Evidence and Clinical Aspects. 2021 , 9, 2984-2993	0

217	ELISpot assay as a diagnostic tool in drug hypersensitivity reactions. 2021 , 495, 113062	2
216	Toxische epidermale Nekrolyse (TEN) âdurch, verstärkt durch oder parallel zu einer SARS-CoV-2-Infektion?. 47,	3
215	Managing respiratory complications in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2021 ,	
214	Clinical and histopathologic characteristics of submandibular gland in Stevens-Johnson syndrome: A comparative study. 2021 ,	
213	HLA-B*15:11 status and carbamazepine-induced severe cutaneous adverse drug reactions in HLA-B*15:02 negative Chinese. 2021 ,	1
212	Erythema multiforme major after chemoradiotherapy on tongue cancer patient. 2021 ,	
211	StevensâJohnson syndrome/toxic epidermal necrolysis overlap syndrome due to oral phenytoin. 2021 , 10, 115	
210	Erythema Multiforme, StevensâJohnson Syndrome and Toxic Epidermal Necrolysis. 1-22	4
209	Cutaneous Diseases and the Esophagus. 763-781	1
208	Dermatologic Toxicities. 2010 , 361-380	1
207	Cutaneous Disorders in the Intensive Care Unit. 2012 , 129-142	1
206	Inflammatory Disorders Affecting the Epidermis of the Vulva. 2015 , 31-69	2
205	Genital Herpes. 2011 , 217-242	1
204	Schwere arzneimittelinduzierte Hautreaktionen: Pemphigus vulgaris, bullöses Pemphigoid, generalized bullous fixed drug eruption, Erythema exsudativum multiforme majus, Stevens-Johnson-Syndrom und toxisch-epidermale Nekrolyse. 1995 , 89-95	1
203	Severe Cutaneous Adverse Drug Reactions. 2020 , 1-7	1
202	Cutaneous Adverse Drug Reactions: StevensâJohnson Syndrome and Toxic Epidermal Necrolysis. 2016 , 393-404	1
201	Lichenoid and interface dermatitis. 2012 , 219-258	0
200	The Hypersensitivity Syndromes. 2011 , 454-482	2

199	Long-term Progression of Ocular Surface Disease in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. 2020 , 39, 745-753	8
198	HLA-A*24:02 associated with lamotrigine-induced cutaneous adverse drug reactions: A systematic review and meta-analysis. 2020 , 99, e23929	3
197	A case of toxic epidermal necrolysis caused by trimethoprim-sulfamethoxazole. 2014 , 2014,	6
196	induced rash and mucositis: a recently described entity. 2017 , 2017,	15
195	Toxic epidermal necrolysis: the red eye and red herrings in casualty. 2018 , 2018,	1
194	Pediatric SJS-TEN: Where are we now?. 2020 , 9,	6
193	Recent advances in managing and understanding Stevens-Johnson syndrome and toxic epidermal necrolysis. 2020 , 9,	18
192	The Effect of Intravenous Immunoglobulin Combined with Corticosteroid on the Progression of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Meta-Analysis. 2016 , 11, e0167120	30
191	Reações cutâneas graves adversas a drogas - aspectos relevantes ao diagnóstico e ao tratamento - Parte I - Anafilaxia e reações anafiláticas, eritrodermias e o espectro clínico da síndrome de Stevens-Johnson & necrólise epidérmica tóxica (Doença de Lyell). 2004 , 79, 471-488	7
190	Analysis of clinical experience of children with toxic epidermal necropysis. 2020 , 65, 181-186	0
189	Internet Accounts of Serious Adverse Drug Reactions. 2012 , 35, 1159	4
188	Clinical Phenotypes of Severe Cutaneous Drug Hypersensitivity Reactions. 2019 , 25, 3840-3854	5
187	A Case of Toxic Epidermal Necrolysis due to Acetaminophen. 2004 , 66, 385-388	1
186	Stevens-Johnson syndrome complicating adalimumab therapy in Crohn's disease. 2009 , 15, 4449-52	26
185	Direct costs of severe cutaneous adverse reactions in a tertiary hospital in Korea. 2019 , 34, 195-201	11
184	Varicella Infection: A Rare but Important Consideration in a Toxic Epidermal Necrolysis-like Eruption. 2020 , 65, 327-328	0
183	Toxic Epidermal Necrolysis During Cotherapy with Ipilimumab and Nivolumab. 2018 , 1, 78-81	5
182	Severe Cutaneous Adverse Reactions to Antiepileptic Drugs: A Nationwide Registry-Based Study in Korea. 2019 , 11, 709-722	14

- 181 A Case of Generalized Seizure after Toxic Epidermal Necrolysis. **2020**, 32, 334-336 1
- 180 Fatal drug reaction due to allopurinol therapy in a 72-year-old man. **2005**, 129, e183-4 3
- 179 Clinical parameters and biological markers associated with acute severe ocular complications in Stevens-Johnson syndrome and toxic epidermal necrolysis. **2021**, 11, 20275 1
- 178 Reactions to Medications. **2000**, 403-430
- 177 Schwere Arzneimittelreaktionen. **2001**, 410-416 1
- 176 Infectious Diseases in Toxic Epidermal Necrolysis. **2001**, 861-874
- 175 Skin and Bone Disorders. **2006**, 327-357 2
- 174 Malignant Melanoma. **2007**, 291-302
- 173 Pharyngitis/Tonsillitis. **2007**, 511-526
- 172 Erythème polymorphe : ^ propos de 3 cas cliniques. **2007**, 261-275
- 171 Inflammatory and Purpuric Eruptions. **2008**, 311-342 2
- 170 Urticaria and Erythema Multiforme. **2008**, 449-453
- 169 Dermatologic Diseases. **2009**, 741-815
- 168 ANTIBACTERIAL DRUGS. **2010**, 1-443
- 167 Entzündliche Erkrankungen des Pharynx. **2010**, 429-463
- 166 Stevens-Johnson Syndrome and Its Manifestation in Oral Cavity. **2010**, 110, 39-44
- 165 Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. **2011**, 599-611 1
- 164 ???Stevens-Johnson?????????????????????. **2011**, 18, 655-656

163 Schwere kutane Arzneimittelreaktionen. **2012**, 582-588

162 Field Studies. 347-363

161 Desquamative Gingivitis. **2012**, 111-126

160 A Practitioner's Guide to Prescribing Lamotrigine for Adults with Intellectual Disabilities. **2012**, 155-184

159 Biomarkers associated with severe cutaneous adverse reactions. **2012**, 431-439

158 Drug Eruptions. **2013**, 43-55

157 LAMOTRIGINE INDUCED TOXIC EPIDERMAL NECROLYSIS IN A PATIENT WITH BIPOLAR DISORDER. **2013**, 2, 82-85

156 Field Studies. 178-189

155 Dermatological Disorders. **2014**, 249-257

154 Life-threatening (Serious) Dermatologic Adverse Events. 310-318

153 Okultē Oberflēche ā nicht infektiō. **2014**, 117-180

152 Penicillamine-induced toxic epidermal necrolysis in a patient with Wilson disease. **2014**, 2, 302

151 Severe Cutaneous Adverse Reaction. **2014**, 87, 665

3

150 Unerwūnschte Arzneimittelreaktionen. **1997**, 346-350

149 Haut. **1997**, 483-590

148 Erythema Multiforme. **2015**, 267-276

2

147 The Acutely Ill Patient with Fever and Rash. **2015**, 732-747.e4

1

146 Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. **2015**, 319-326

1

- 145 Erythema Multiforme and Drug Reactions. **2015**, 65-76
- 144 Pharmacogenetics of Adverse Drug Reactions. **2015**, 109-156
- 143 Fundamental Study of Improving an Efficient Assay in Patient of Drug-induced Allergy. **2015**, 41, 11-17
- 142 Toxic Epidermal Necrolysis Syndrome and Stevens-Johnson Syndrome. **2015**, 128-137
- 141 Schwere blasenbildende Hautreaktionen. **2016**, 389-401
- 140 Toxic Epidermal Necrolysis. **2016**, 163-167
- 139 Exfoliating and Necrotizing Soft Tissue Diseases. **2016**, 219-228
- 138 Dermatologic Emergencies in Oncologic Patients. **2016**, 333-349
- 137 Manifestations orales de l'érythème polymorphe : présentation de cas cliniques. **2016**, 22, 137-143
- 136 Idiosyncratic Adverse Reactions to Psychotropic Medications. **2016**, 46, 456-465
- 135 Dermatologic Emergencies. **2017**, 303-321
- 134 Current perspective on the role of TNF inhibitors in treating patients with toxic epidermal necrolysis. **2016**, 30, 24-27
- 133 Tedavi sürecinde akut böbrek yetmezliği ile Steven-Johnson sendromu gelişen Bruselloz olgusu. **2016**, 41, 818-819
- 132 Multifactorial Diseases with Immunological Involvement. **2017**, 221-258
- 131 Adverse Medication Reactions. **2017**, 439-467 1
- 130 Management of Severe Skin Eruptions. **2017**, 759-763
- 129 White and Red Lesions of the Oral Mucosa. **2017**, 1-42 1
- 128 Schwere kutane Arzneimittelreaktionen. **2017**, 1-8

127 Cell Death and Skin Disease. **2017**, 201-217

126 Experience of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in a Regional Hospital: 70 Cases in 7 Years. **2017**, 92, 171-176

125 Differential Diagnosis. **2018**, 361-464

124 Stevens-Johnson Syndrome : A Case Report. **2017**, 44, 455-460

1

123 Dermatologic Adverse Events. **2018**, 597-620

1

122 Pediatric Oral Medicine. **2018**, 1-79

121 Erythema Multiforme and Stevens-Johnson Syndrome. **2018**, 303-309

120 Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome due to oral cefuroxime. **2019**, 8, 155

119 Entzündliche Erkrankungen des Pharynx. **2019**, 365-394

118 Ophthalmological perspectives of toxic epidermal necrolysis. **2019**, 7, 254

117 Epidermal Necrolysis Spectrum from Basic Theory to Practice Essentials. **2020**, 549-557

116 Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. **2020**, 1-11

115 Stevens Johnson Syndrome â Steven Who? And Why I Should Care About His Johnson?â **2020**, 547-558

114 The Aetiology of Anaphylaxis. **2020**, 13-161

113 Serum Soluble OX40 as a Diagnostic and Prognostic Biomarker for Drug-Induced Hypersensitivity Syndrome/Drug Reaction with Eosinophilia and Systemic Symptoms. **2021**,

1

112 Drug Hypersensitivity Reactions. **2022**, 40, 39-55

0

111 Erythema Multiforme, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis. **2022**, 1089-1099

110 The Role of Detection of Drug-Specific Mediator-Releasing Cells to Diagnose Different Phenotypes of Severe Cutaneous Adverse Reactions. **2021**, 13, 896-907

0

109 Immune Mediated Diseases. **2020**, 511-530

108 A case of toxic epidermal necrolysis due to topiramate. **2020**, 8, 102

107 Lichenoid and Interface Dermatitis. **2020**, 41-92

106 «Acute skin failure», unreasonably lost term. **2020**, 65, 133-137

105 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Guide for Nurses. **2020**, 31, 281-295 ○

104 The present perspective on the administration of intravenous immunoglobulins in patients with toxic epidermal necrolysis. **2020**, 34, 135-141

103 Erosive cheilitis as an early manifestation in DRESS syndrome. **2021**, 9, e05123 ○

102 Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study. **2021**, ○

101 Plasmapheresis as a promising treatment option in apalutamide-associated toxic epidermal necrolysis. **2021**, ○

100 Epithelial Necrolysis. **2021**, 409-422

99 Drug Allergy and Cutaneous Adverse Reactions. **2022**, 268, 195-212

98 The role of frozen section in the rapid diagnosis of severe cutaneous adverse drug reactions. **2021**, 12, 78

97 Cyclosporine in Stevens-Johnson syndrome and toxic epidermal necrolysis: Experience from a tertiary care centre of South Rajasthan. **2021**, 12, 116 1

96 Factors predicting the outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis: A 5-year retrospective study. **2021**, 12, 258 1

95 Annular urticarial lesions.. **2021**, ○

94 Copyright. **2010**, 7-48

93 Erythema Multiforme. **2021**, 401-408

92 Comparing the Accuracy of ABCD-10 and SCORTEN in Predicting the In-Hospital Mortality of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Multi-Institutional Study from Central China. **2021**, 1-9 ○

- 91 The Clinical Characteristics, Putative Drugs, and Optimal Management of 62 Patients With Stevens-Johnson Syndrome and/or Toxic Epidermal Necrolysis: A Retrospective Observational Study.. **2022**, 13, 23-31 ○
- 90 Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients.. **2022**, 10781552221074623
- 89 Stevens Johnson Syndrome/Toxic Epidermal Necrolysis and Erythema Exsudativum Multiforme. **2022**, 165-176
- 88 Lab-Based Culprit Drug Identification Methods for Cutaneous Drug Eruptions: A Scoping Review.. **2022**, 12034754211073667
- 87 Differential Diagnosis of Lesions.. **2022**, 44, 23-28
- 86 Inhibition of tumor necrosis factor improves conventional steroid therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.. **2022**, ○
- 85 Leflunomide-induced liver injury: Differences in characteristics and outcomes in Indian and US registries.. **2022**, ○
- 84 Clinical and Epidemiological Features of Patients with Drug-Induced Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Iran: Different Points of Children from Adults.. **2022**, 2022, 8163588 ○
- 83 Annular drug eruptions.. **2021**, ○
- 82 Functional and Structural Characteristics of HLA-B*13:01-Mediated Specific T Cells Reaction in Dapsone-Induced Drug Hypersensitivity.
- 81 Improvement of Mortality Prognostication in Patients With Epidermal Necrolysis: The Role of Novel Inflammatory Markers and Proposed Revision of SCORTEN (Re-SCORTEN).. **2021**, ○
- 80 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis-Coordinating Research Priorities to Move the Field Forward.. **2022**, ○
- 79 Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization.. **2022**, ○
- 78 Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome.. **2022**, 3, CD013130 1
- 77 Recognizing Drug Hypersensitivity in Pigmented Skin.. **2022**, 42, 219-238 1
- 76 Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review.. **2022**, 15, 345-351 ○
- 75 Undiagnosed and Rare Diseases in Critical Care: Severe Mucocutaneous Medication Reactions.. **2022**, 38, 243-269
- 74 Challenges in the management of bilateral eyelid closure in Stevens-Johnson Syndrome.. **2022**, 26, 101473

- 73 Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization Vigibase.. **2021**, 0
- 72 Multi-state model for predicting ocular progression in acute Stevens-Johnson syndrome/toxic epidermal necrolysis.. **2021**, 16, e0260730 0
- 71 Stevens-Johnson syndrome linked to tramadol use and ultraviolet radiation. **2021**, 2, e0176
- 70 Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. **2021**, 30, 1012-1019 2
- 69 Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.. **2022**, 2486, 37-54 0
- 68 Non-neoplastic skin disease. 291-362
- 67 Image1.tif. **2018**,
- 66 Image2.tif. **2018**,
- 65 Table1.doc. **2018**,
- 64 Severe Cutaneous Adverse Drug Reactions. **2022**, 625-631
- 63 Clinical characteristics of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A single-center study.. **2022**, 12, e17 0
- 62 Relationship between Atopic Disease and Acute Ocular and Systemic Outcomes in Patients with Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.. **2022**, 1-5
- 61 Carbamazepine Induced Stevens-Johnson Syndrome That Developed into Toxic Epidermal Necrolysis: Review of the Literature.. **2022**, 2022, 6128688 0
- 60 Cutaneous drug reactions with systemic features. **2013**, 747-755.e2 1
- 59 The Hypersensitivity Syndromes. **2016**, 467-494.e6 2
- 58 Microbial Keratitis in Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Experience From a Tertiary Centre in Taiwan.. **2022**,
- 57 IFN- γ ELISpot in Severe Cutaneous Adverse Reactions to First-line Anti-tuberculosis Drugs in an HIV Endemic Setting. **2022**, 0
- 56 Management of oral mucosal lesions in salicylate sensitive stevensâJohnson syndrome âA case report. **2021**, 32, 537 0

- 55 Evaluation of patients with erythema exudativum multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis treated at our department during the previous 9-year period.
- 54 Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN. **2022**, 24, 307-319
- 53 Clinical features and outcomes in children with Stevens-Johnson syndrome and toxic epidermal necrolysis.
- 52 Psychotherapeutic interventions for burns patients and the potential use with Stevens-Johnson syndrome and toxic epidermal necrolysis patients: A systematic integrative review. **2022**, 17, e0270424 ○
- 51 Iodinated contrast induced Stevens-Johnson Syndrome, report of a rare complication for a common imaging agent. **2022**, ○
- 50 The role of treatment with plasma exchange therapy in two pediatric toxic epidermal necrolysis cases related to COVID -19. ○
- 49 Risk factors for sepsis and effects of pretreatment with systemic steroid therapy for underlying condition in SJS/TEN patients: Results of a nationwide cross-sectional survey in 489 Japanese patients. **2022**,
- 48 Stevens-Johnson syndrome in children. **2022**, 34, 341-348
- 47 Managing the ADR of Stevens-Johnson syndrome/toxic epidermal necrolysis.
- 46 Clinical Manifestations and Genetic Influences in Sulfonamide-Induced Hypersensitivity. Volume 14, 113-124 1
- 45 Skin testing and drug provocation tests in epidermal necrolysis: a French experience. **2022**, ○
- 44 Comparing the effectiveness of two diagnostic approaches for the interpretation of oral radiographic lesions by dental students.
- 43 IL-15/IL-15R α in SJS/TEN: Relevant Expression of IL15 and IL15RA in Affected Skin. **2022**, 10, 1868
- 42 "Drugs and the Skin" A concise review of cutaneous adverse drug reactions. 1
- 41 Functional and structural characteristics of HLA-B*13:01-mediated specific T cells reaction in dapsone-induced drug hypersensitivity. **2022**, 29, ○
- 40 Chronic kidney disease is potentially an independent prognostic factor for death in Stevens-Johnson syndrome and toxic epidermal necrolysis patients. 9,
- 39 Sykdommer som affiserer hud og munnslimhinne. **2006**, 116, ○
- 38 Immune-Related Uncommon Adverse Events in Patients with Cancer Treated with Immunotherapy. **2022**, 12, 2091 1

37	Drug Allergy: A 2022 Practice Parameter Update. 2022 ,	1
36	Acetaminophen-induced Stevens-Johnson syndrome with lethal lung injury: A case report. 2022 , 10,	0
35	Increased expression of human herpes virus 6 receptor CD134 / OX40 in skin lesions of patients with drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms.	0
34	Toxic Epidermal Necrolysis: A Case Report on a Drug-Induced Phenomenon. 2022 ,	0
33	Case report: Development of vanishing bile duct syndrome in Stevens-Johnson syndrome complicated by hemophagocytic lymphohistiocytosis. 9,	0
32	Accuracy of SCORTEN in predicting mortality in toxic epidermal necrolysis. 2022 , 22,	0
31	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Children: A Literature Review of Current Treatments. 83-89	1
30	Dermatoses of the Oral Cavity and Lips. 1-144	0
29	Urticaria and Erythema Multiforme. 2023 , 466-472.e2	0
28	Clinical features and prognostic factors of severe cutaneous adverse drug reactions: A single-center retrospective study of 209 cases in China. 2023 , 114, 109530	0
27	Therapeutic management of carbamazepine's complications in front of essential trigeminal neuralgia. 2022 , 8, 100372	0
26	Serum levels of C-C motif chemokine ligand 2 and interleukin-8 as possible biomarkers in patients with toxic epidermal necrolysis accompanied by acute respiratory distress syndrome.	0
25	TNF- α -mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens-Johnson syndrome/ toxic epidermal necrolysis.. 2022 ,	0
24	TEN mimics: Classification and practical approach to toxic epidermal necrolysis-like dermatoses. 1-10	0
23	Clinical value of the prognostic nutritional index and red blood cell distribution width-to-albumin ratio for the prediction of severity of and mortality associated with Stevens-Johnson syndrome/toxic epidermal necrolysis.	0
22	Steven Johnson Syndrome in a 102-Year-Old Woman in Saudi Arabia: A Case Report. 2022 ,	0
21	Ocular surface involvement and histopathologic changes in the acute stage of Stevens- Johnson Syndrome and Toxic Epidermal Necrolysis: a cross-sectional study.	0
20	Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: Diverse effects on systemic inflammation.	0

- 19 Clinical and Liver Biochemistry Phenotypes, and Outcome in 133 Patients with Anti-seizure Drug-Induced Liver Injury. ○
- 18 Necr sis epid mica t xica en paciente infectado por virus de inmunodeficiencia humana. **2012**, 15, 68-72 ○
- 17 Drug Patch Testing in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis: A Systematic Review. **2023**, ○
- 16 Management of Large conjunctival cysts in a patient with Stevens-Johnson syndrome; a case report and review of the literature'. ○
- 15 Drug-induced liver injury: An overview and update. **2023**, ○
- 14 Anesthesia in High-Risk Surgical Patients with Uncommon Disease. **2023**, 323-343 ○
- 13 Sertraline induced Stevens-Johnson syndrome - A case series. **2023**, 0 ○
- 12 Validation of a genotyping technique for a surrogate marker of HLA-B58:01 for allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in the Japanese population. **2023**, 49, 100495 ○
- 11 Worldwide Prevalence of Antibiotic-Associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. **2023**, 159, 384 ○
- 10 Effects of dosage in new users of lamotrigine inducing epidermal necrolysis: Results of the German Registry of Severe Skin Reactions. ○
- 9 Blasenbildende Dermatosen und Hauterkrankungen. **2022**, 93-99 ○
- 8 Evaluation of Plasmapheresis vs Immunoglobulin as First Treatment After Ineffective Systemic Corticosteroid Therapy for Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. ○
- 7 Reality of drug-induced erythema multiforme: A French pharmacovigilance study. **2023**, ○
- 6 Sutureless Amniotic Membrane Transplantation Using Pediatric Nasogastric Tube for Patients With Acute Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis. **2023**, Publish Ahead of Print, ○
- 5 Lip synechiae: A sequelae of carbamazepine-induced erythema multiforme. A case report and review of current perspectives and controversies. ○
- 4 Adverse Drug Reactions. **2023**, 749-806 ○
- 3 Long-Term Benefits of Tear Exchangeable Limbal-Rigid Contact Lens Wear Therapy in Stevens-Johnson Syndrome Cases. **2023**, Publish Ahead of Print, ○
- 2 Schwere kutane Arzneimittelreaktionen bei Kindern. ○

- 1 Biologic TNF- α inhibitors for StevensâJohnson Syndrome, Toxic Epidermal Necrolysis, and TEN-SJS Overlap: A Study-Level and Patient-Level Meta-Analysis. o